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Despite advancements in treating ruptured cerebral aneurysms, an aneurysmal subarachnoid hemorrhage (aSAH) is still a grave 
cerebrovascular disease associated with a high rate of morbidity and mortality. Based on the literature published to date, world-
wide academic and governmental committees have developed clinical practice guidelines (CPGs) to propose standards for disease 
management in order to achieve the best treatment outcomes for aSAHs. In 2013, the Korean Society of Cerebrovascular Surgeons 
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INTRODUCTION
Aneurysmal subarachnoid hemorrhage (aSAH) is a grave 
cerebrovascular disease with a high mortality rate of 40–60% 
and an incidence of 9–23 persons per 10000057,69,312). To im-
prove the treatment outcomes and advance clinical studies 
and research, many governmental and academic committees 
have made and revised the clinical practice guidelines (CPGs) 
for aSAH. The Korean Society of Cerebrovascular Surgeons 
issued a Korean version of the CPGs for aSAH; the writing 
group consisted of Quality Control Committee members 
from the Korean Society of Cerebrovascular Surgeons and 
Korean Academy of Rehabilitation Medicine. The CPGs for 
aSAH were developed between 2013 and 2016, and a de novo 
method was implemented for the development strategy rather 
than an adaptation approach. The writing group searched for 
domestic and foreign articles published in English between 
January 1970 and December 2015 using several search engines 
such as MEDLINE (www.ncbi.nlm.nih.gov/pubmed), Embase 
(www.embase.com), Scopus (www.scopus.com), KoreaMed 
(www.koreamed.org), and Google Scholar (scholar.google.
co.kr); the authors referenced three major foreign CPGs from 
the American Heart Association/American Stroke Association 
(AHA/ASA) in 201259), European Stroke Organization (ESO) 
in 2013312) and Japanese Society on Surgery for Cerebral Stroke 
(JSSCS) in 200857). All the references were classified into levels 
of evidence (LOE), and each recommendation was determined 
based on the predetermined grades of recommendation 
(GOR) (Table 1)274). Lastly, all the LOEs and GORs were re-
viewed and approved by the internal and external validations 
of the Korean Society of Cerebrovascular Surgeons as well as 
related academic societies such as the Society of Korean Endo-
issued a Korean version of the CPGs for aSAHs. The group researched all articles and major foreign CPGs published in English until 
December 2015 using several search engines. Based on these articles, levels of evidence and grades of recommendations were 
determined by our society as well as by other related Quality Control Committees from neurointervention, neurology and rehabili-
tation medicine. The Korean version of the CPGs for aSAHs includes risk factors, diagnosis, initial management, medical and surgi-
cal management to prevent rebleeding, management of delayed cerebral ischemia and vasospasm, treatment of hydrocephalus, 
treatment of medical complications and early rehabilitation. The CPGs are not the absolute standard but are the present reference 
as the evidence is still incomplete, each environment of clinical practice is different, and there is a high probability of variation in the 
current recommendations. The CPGs will be useful in the fields of clinical practice and research.
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Table 1. Level of evidence and grade of recommendation in the Korean clinical practice guideline for aneurysmal subarachnoid hemorrhage
Level of evidence (LOE)
Ia Meta-analysis of randomized controlled trials
Ib At least one randomized controlled trial
IIa At least one well-designed controlled study without randomization
IIb At least one other type of well-designed quasi-experimental study
III Descriptive studies such as comparative studies, correlation studies and case studies
IV Expert committee reports, clinical experiences and opinions of respected authorities
Grade of recommendation
A (LOE Ia and Ib) Recommendation should be followed
B (LOE IIa, IIb, and III) Recommendation being reasonable or recommended to do
C (LOE IV) Recommendation being considered to do 
Good clinical practice (GCP) Consensus opinion of the guideline development group
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vascular Neurosurgeons, Korean Society of Interventional 
Neuroradiology, Korean Stroke Society, and Korean Academy 
of Rehabilitation Medicine. The authors clearly note that the 
ultimate discretion always depends on a physician’s decision, 
considering the various situations of related factors for each 
patient; therefore, the presented CPGs should not limit the 
medical practice of healthcare professionals nor provide a ref-
erence for insurance claims. Furthermore, the CPGs should 
never serve as a basis for legal judgment of the medical care 
provided in a specific clinical situation.
RISK FACTORS
In the working-age population, approximately 30% of un-
ruptured cerebral aneurysms are prone to bleed during the life-
long follow-up period169). Risk factors may be classified based 
on the formation, growth and rupture of aneurysms. Indepen-
dent and preventive risk factors for aSAHs are tobacco smok-
ing, alcohol misuse and hypertension35,88,145,165).
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Treatment of high blood pressure with antihypertensive 
medication is recommended to prevent ischemic stroke, intra-
cerebral hemorrhage, and cardiac, renal, and other end-organ 
injury (class I; LOE A). 
2. Hypertension should be treated, and such treatment may 
reduce the risk of aSAH (class I; LOE B).
3. Tobacco use and alcohol misuse should be avoided to re-
duce the risk of aSAH (class I; LOE B).
4. In addition to the size and location of the aneurysm and 
the patient’s age and health status, it might be reasonable to 
consider morphological and hemodynamic characteristics of 
the aneurysm when discussing the risk of aneurysm rupture 
(class IIb; LOE B).
5. Consumption of a diet rich in vegetables may lower the risk 
of aSAH (class IIb; LOE B).
6. It may be reasonable to offer noninvasive screening to pa-
tients with familial (at least 1 first-degree relative) aSAH and/or 
a history of aSAH to evaluate for de novo aneurysms or late re-
growth of a treated aneurysm, but the risks and benefits of this 
screening require further study (class IIb; LOE B).
7. After any aneurysm repair, immediate cerebrovascular im-
aging is generally recommended to identify remnants or recur-
rence of the aneurysm that may require treatment (class I; LOE B).
ESO (2013)312)
1. Screening should in general not be advised in the case of 
only 1 affected first-degree relative.
2. If 2 or more first-degree relatives are affected, the lifetime 
risk of SAH in the other relatives is considerable, and screen-
ing should be considered (LOE III; level C).
JSSC (2008)57)
1. Control of hypertension and cessation of smoking in indi-
viduals with these risk factors are desirable to reduce the risk of 
SAH (GOR A).
2. Results on the correlation between psychophysiological 
tension and the incidence of SAH are variable (GOR C1).
3. The risk of harboring an aneurysm was 4% in individual 
having affected close relatives (first-degree relatives) (GOR A).
Evidence
Tobacco smoking has been shown to be the most important 
risk factor for aSAHs, with a relative risk (RR) of 2.2 (95% con-
fidence interval [CI] 1.3–3.6) and an odds ratio (OR) of 3.1 (95% 
CI 2.7–3.5)88). Aneurysm size and location, patient age (inverse-
ly) and tobacco smoking are independent risk factors of aneu-
rysm rupture144,146,147,349). As found in a prospective study, smok-
ing and female sex are independent risk factors that affect the 
formation and growth of aneurysms148). The risk of rupture is 
higher with a faster growing aneurysm. Particularly, tobacco 
smoking causes faster growth of aneurysms in females than in 
males35).
Alcohol consumption is less established as a risk factor for 
aSAHs. In several cohort and case-control studies, alcohol mis-
use was shown to increase the risk of aSAHs in both males and 
females, independently31,88,145,165,194,286). The RR of heavy alcohol 
consumption along with smoking tobacco is 6.0 (95% CI 1.8–
20.1)148). Moreover, the OR of alcohol consumption becomes 10.5 
(95% CI 1.9–56.4)47).
The incidence of hypertension (20–45%) in aSAH patients is 
slightly higher than in the general population. The incidence of 
aSAHs from hypertension increased minimally after statistical 
correction145,194); however, hypertension is still an important risk 
factor in the combination of all cohort and patient control stud-
J Korean Neurosurg Soc 61 | March 2018
130 https://doi.org/10.3340/jkns.2017.0404.005
ies88). In a long-term cohort study, hypertension was not related 
to the formation and growth of aneurysms; additionally, blood 
pressure did not correlate well with the formation or growth of 
aneurysms148). However, the administration of antihypertensive 
drugs decreased the risk of aneurysm formation148).
Recently, a family history of cerebral aneurysms was suggest-
ed as evidence of a genetic relationship165,276,277,342). The degree of 
tobacco smoking and alcohol consumption is also somewhat 
affected by genetic factors49). Less than 10% of aSAHs are attrib-
uted to only first-degree relatives, and 5–8% are attributed to 
first- or second-degree relatives165,283,342). When more than two 
first-degree relatives have aSAHs, the incidence of an aneurysm, 
determined using a screening test, is estimated to be approxi-
mately 10%32-34,40-42,107,258,293,314). A family history of polycystic 
kidney disease increases the risk of aSAHs272).
It is difficult to predict the individual risks of aneurysm growth 
and rupture. On the follow-up magnetic resonance imaging 
(MRI), large aneurysms (more than 8 mm in diameter) are at a 
higher risk for growth and rupture with time44). Regarding the 
risk of aneurysm rupture, it is recommended to consider the 
morphologic and hemodynamic characteristics of an aneurysm 
in addition to the size and location of an aneurysm and the pa-
tient’s age and health status71,134,262). A detailed discussion of the 
risk of aneurysm rupture is included in the Treatment Guide-
lines for unruptured aneurysms by the Korean Society of Cere-
brovascular Surgeons published in 2011, and the main objective 
of this guideline is to suggest treatment guidelines for aSAHs 
caused by ruptured aneurysms297); therefore, a concrete descrip-
tion is not mentioned here.
There are many other risk factors in addition to the prescribed 
risk factors mentioned above. There are reports of non-Cauca-
sian individuals having a high risk of aSAH; in contrast, hor-
mone replacement therapy in females, hypercholesterolemia 
and diabetes mellitus decrease the risk of rupture88). 
In patients with treated ruptured aneurysms, the annual inci-
dence of de novo aneurysm formation is 0.6–0.9%148,329,346). Fe-
male sex and tobacco smoking increase the risk of de novo an-
eurysm formation148). De novo aneurysm formation was found 
in 16% (cumulative probability) of 610 patients with a mean MR 
follow-up of 9 years347); in this study, the risk factors for the for-
mation and growth of aneurysms were multiplicity (hazard ra-
tio [HR] 3.2, 95% CI 1.2–8.6), tobacco smoking (HR 3.8, 95% 
CI 1.5–9.4), and hypertension (HR 2.3, 95% CI 1.1–4.9). In a 
CARAT study, recurrent aSAHs are expected from incomplete 
obliteration of aneurysms, developing in approximately 3 days 
and being rare after 1 year140). With an adequately obliterated an-
eurysm after an aSAH, there is a low risk of recurrence for at 
least 5 years; however, some aneurysms treated with coil em-
bolization occasionally require retreatment221,291,350).
Recommendations
1. Tobacco smoking is reasonable to be avoided to reduce the 
risk of aSAHs (LOE III; GOR B).
2. Hypertension is reasonable to be treated to reduce the risk 
of aSAHs (LOE III; GOR B).
3. Excessive alcohol consumption is reasonable to be avoided 
to reduce the risk of aSAHs (LOE III; GOR B).
4. The size and location of an aneurysm and the patient’s age 
and health status is reasonable to be considered when discuss-
ing the risk of aneurysm rupture (LOE III; GOR B).
5. A screening test is recommended for patients with a famil-
iar history of aSAHs, developed in two or more family members 
in a direct line, due to the high risk of an aneurysm or aSAH 
during their lifetime (LOE III; GOR B).
DIAGNOSIS
Grading
Important risk factors related to the prognosis of aSAHs in-
clude initial neurologic status, patient age and hemorrhage 
amount. A unified grading system is required for communica-
tion among physicians and for predicting the prognosis of pa-
tients with aSAHs.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. The initial clinical severity of aSAH should be determined 
rapidly by use of simple validated scales (e.g., Hunt and Hess, 
World Federation of Neurological Surgeons), because it is the 
most useful indicator of outcome after aSAH (class I; LOE B).
ESO (2013)312)
1. It is recommended that the initial assessment of SAH pa-
tients, and therefore the grading of the clinical condition, is 
done by means of a scale based on the Glasgow coma scale (GCS). 
The Prognosis on Admission of Aneurysmal Subarachnoid 
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Hemorrhage (PAASH) scale performs slightly better than the 
World Federation of Neurological Surgeons (WFNS) scale, 
which has been used more often (LOE III; level C).
JSSC (2008)57)
1. Early and accurate diagnosis, as well as treatment by spe-
cialists, is therefore essential (GOR A).
Evidence
Although a Fisher grade which is a computed tomography (CT)-
based grading system for predicting cerebral vasospasm91), does 
not represent the prognosis of a patient, the existence of an in-
traventricular hemorrhage (IVH; Fisher grade 4) has been relat-
ed to a poor prognosis in patients322). The well-known Hunt-Hess 
scale grossly classifies SAH patients into 5 categories based on 
an initial neurologic examination135). However, the Hunt-Hess 
scale uses an obscure definition of neurologic status; thus, there 
is debate as to whether it is a reasonable and reliable grading sys-
tem192). The WFNS committee suggested a grading system to 
classify initial aSAH patients into 5 stages based on the GCS 
and focal neurologic deficit358). However, there is also debate on 
the WFNS scale as the cut-off point was based on consensus and 
not analytic data. The PAASH grading scale based only on the 
GCS was newly suggested; in this scale, consecutive categories 
show significantly different clinical outcomes at 6 months242). In 
a study comparing the WFNS and PAASH scales, both scales 
had a good prognostic value; however, the PAASH scale was 
slightly preferable because it showed a more gradually propor-
tional increase in grade and poor outcome333). The modified 
WFNS scale was suggested by the WFNS committee in 2015, clas-
sifying a GCS of 13 and 14 into different categories (Table 2)288).
Recommendations
1. The initial neurological assessment of patients with aSAHs 
is helpful for predicting the prognosis, and the modified-WFNS 
scale based on the GCS is recommended (LOE III; GOR B).
Diagnostic tools
An accurate diagnosis is a fundamental basis of the initial as-
sessment. When severe headaches, mental deterioration or neu-
rologic deficits occur, the identification of a SAH and the loca-
tion of a ruptured aneurysm are important to make a proper 
treatment plan and predict the prognosis.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. aSAH is a medical emergency that is frequently misdiag-
nosed. A high level of suspicion for aSAH should exist in patients 
with acute onset of severe headache (class I; LOE B).
2. Acute diagnostic workup should include noncontrast head 
CT, which, if nondiagnostic, should be followed by lumbar punc-
ture (class I; LOE B).
3. Magnetic resonance imaging (fluid-attenuated inversion 
recovery, proton density, diffusion-weighted imaging, and gra-
dient echo sequences) may be reasonable for the diagnosis of 
aSAH in patients with a nondiagnostic CT scan, although a 
negative result does not obviate the need for cerebrospinal flu-
id analysis (class IIb; LOE C).
4. CT angiography (CTA) may be considered in the workup 
of aSAH. If an aneurysm is detected by CTA, this study may 
help guide the decision for type of aneurysm repair, but if 
CTA is inconclusive, digital subtraction angiography (DSA) is 
still recommended (except possibly in the instance of classic 
perimesencephalic aSAH) (class IIb; LOE C). 
5. DSA with 3-dimensional rotational angiography is indicat-
ed for detection of aneurysm in patients with aSAH (except when 
the aneurysm was previously diagnosed by a noninvasive an-
giogram) and for planning treatment (to determine whether an 
aneurysm is amenable to coiling or to expedite microsurgery) 
(class I; LOE B). 
ESO (2013)312)
1. CT/CTA and MRI with multiple sequences are equally 
suitable for the diagnosis of SAH within 24 hours (LOEs II; 
level B).
2. CT/CTA and multisequential MRI/magnetic resonance 
Table 2. Three grading scales with criteria per grade
Grade
Criteria per grading scale
WFNS PAASH Modified WFNS
I 15 15 15
II 13–14, no focal deficit 11–14 14
III 13–14, focal deficit 8–10 13
IV 7–12 4–7 7–12
V 3–6 3 3–6
Arabic numerals means Glasgow coma scale. WFNS : World Federation 
of Neurological Surgeons, PAASH : Prognosis on Admission of Aneurys-
mal Subarachnoid Haemorrhage
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angiography (MRA) may confirm the underlying cause.
3. Lumbar puncture must be performed in a case of clinical-
ly suspected SAH if CT or MRI does not confirm the diagnosis 
(LOE II, level B); however, within the first 6–12 hours the dif-
ferentiation between genuine subarachnoidal blood and trau-
matic admixture of blood may be difficult.
4. DSA of all cerebral arteries should be performed if a bleed-
ing source was not found on CTA and the patient has a typical 
basal SAH pattern on CT (LOE II; level B).
5. If no aneurysm was found, CTA or DSA should be repeat-
ed as described below : SAH without aneurysm (LOE III; level C).
JSSC (2008)57)
1. The importance of recognizing a warning leak cannot be 
overemphasized (GOR A). 
2. Among stroke patients with sudden headache, there is a 
high likelihood of SAH if nuchal rigidity or seizure, without 
other focal neurological deficits, is present (GOR B).
3. In the interpretation of the CT, it should be noted that in-
tracerebral hematoma may be documented as the main find-
ing, or ventricular dilatation (especially dilation of the inferior 
horn) as the only finding of ruptured aneurysm (GOR B).
4. Diagnostic lumbar puncuture is highly recommended if the 
initial CT scan is negative despite the presence of warning signs, 
or if SAH is clinically strongly suspected despite the delay be-
tween onset and presentation (GOR A).
5. Evolvement of MRI techniques (gradient echo T2* or fluid 
attenuated inversion recovery) may improve the diagnosis of 
SAH, especially in the subacute and chronic stages (GOR B).
6. Once SAH is diagnosed, an immediate investigation for an 
intracranial aneurysm must be undertaken with conventional 
cerebral angiography or DSA, a technique increasingly used 
(GOR A).
7. Although the localization of the ruptured aneurysm is 
sometimes possible with CT finding, evaluation with cerebral 
angiography including all of the intracranial vessels is recom-
mended because of the possibility of coexisting unruptured 
aneurysms (GOR A).
8. Re-examination (e.g., repeat angiography) is indispensable 
if the source of bleeding is not indicated in the first evaluation 
(GOR A).
9. These patients are reported to have favorable outcome and 
repeat angiography is not necessary (GOR B).
10. Although the detection rate for small (under 2 mm in di-
ameter) aneurysms may be low, it is a highly useful modality for 
assessing the 3D orientation of vessels around the aneurysm 
(GOR B).
11. Because of the comparable sensitivity to conventional ce-
rebral angiography and less invasiveness (GOR B), MRA is 
widely used as a screening modality.
12. MRA is unsuitable as the initial test for aneurysm detec-
tion (GOR B).
13. Transcranial ultrasonography, with a sensitivity of ap-
proximately 50–80% for known aneurysm previously detected 
on other modality, is considered to be nothing more than a sup-
plementary test (GOR A).
Evidence
A headache is the typical symptom of an aSAH, and approx-
imately 80% of alert patients describe it as the worst pain in 
their life21). A headache abruptly occurs and immediately reach-
es its peak intensity (i.e., a thunderclap headache), and 10–43% 
of patients experience a warning or sentinel headache before an 
aneurysm ruptures64,254). Therefore, when an SAH is clinically 
suspected, performing a brain CT is the best way to discover the 
SAH83,84,139,171). It has been reported that 5.4% of patients who 
visit the emergency room presenting with abrupt and severe 
headaches were misdiagnosed when they were alert or had no 
neurologic deficits. According to a recent study, when a patient 
older than 15 years with no previous medical history nor men-
tal deterioration presents with a severe non-traumatic headache 
reaching its peak severity within one hour, a CT scan is recom-
mended if the headache is accompanied by at least one of the 
following risk factors (Ottawa SAH rule) : age older than 40 years, 
neck stiffness or pain, loss of consciousness, headache occur-
ring during activity, thunderclap headache reaching the peak 
intensity within one hour, and limitation of neck flexion dur-
ing physical examination23,249,250).
The sensitivity of non-contrast CT is as high as 100% for the 
diagnosis of an SAH within three days from the onset; however, 
lumbar puncture may be required to confirm an SAH beyond 
5 to 7 days from the onset because there is an increased possi-
bility of a false negative60). Moreover, several MRI techniques 
such as f luid-attenuated inversion recovery imaging, proton 
density, diffusion-weighted imaging and gradient echo imag-
ing may be helpful in diagnosing the acute stage of an SAH 
within 4 days from the onset. Nonetheless, such MR tech-
niques are still inferior to lumbar puncture for the diagnosis 
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of an SAH90,161,206,208,302).
When an SAH is diagnosed from non-contrast CT, CT angi-
ography may be applied to identify the ruptured aneurysms and 
to establish the treatment plan. However, CT angiography is less 
sensitive for small aneurysms less than 3 mm in diameter, and 
DSA is preferred for aneurysm diagnosis74,213). There is some de-
bate as to whether DSA should be performed in cases of typical 
perimesencephalic SAHs because CT angiography is considered 
sufficient to exclude aneurysm rupture2,39,82,208). Multi-detector 
CT angiography with 16- or 64-channel detectors is superior to 
single- or 4-channel detectors in the diagnosis of aneurysms, 
particularly those less than 4 mm in diameter215).
It is generally accepted that DSA should be performed when 
an aneurysm is not detected on the initial CT angiography in 
cases of diffuse SAHs from non-contrast CT. There is still some 
debate on the cases of perimesencephalic SAHs, though some 
reports indicate that an aneurysmal SAH may be excluded when 
an aneurysm is not detected from CT angiography2,39,208). There 
is another opinion that DSA should be performed instead of CT 
angiography for SAH patients presenting with loss of conscious-
ness82); however, according to a meta-analysis of retrospective 
studies151), an aneurysmal SAH may be excluded based on a neg-
ative finding from CT angiography with at least 64 multi-chan-
nel in cases of isolated perimesencephalic SAHs which are de-
fined as the presence of blood confined in the perimesencephalic 
cistern with possible extension to ambient cistern and proximal 
stems of the sylvian fissure, with no history of trauma, diffuse 
SAH, thick blood above the perimesencephalic cistern and IVH 
on the initial noncontrast CT.
In approximately 14% of cases of diffuse SAH detected from 
non-contrast CT and no aneurysm from the initial DSA, small 
aneurysms were found from the delayed repetitive DSA2). Ac-
cording to a recent meta-analysis18), aneurysms were identified 
on the repetitive DSA in approximately 10% of patients with 
diffuse SAHs and no aneurysms detected on the initial CT an-
giography and DSA. However, there is still some debate on the 
timing of repetitive DSA. There was a report that causative cere-
brovascular lesions were identified in 8% of 39 patients from re-
petitive CT angiography or DSA at a mean time interval of 34 
days from the last check-up who showed no lesions on the ini-
tial CT angiography or DSA and 7-day delayed DSA69).
Recommendations
1. Brain CT is recommended for patients presenting with a 
sudden and severe headache and neurologic deficits. For patients 
with no neurological deficits, brain CT is still recommended 
when the patient is older than 40 years and complains of neck 
pain and stiffness, loss of consciousness, and an abrupt and 
thunderclap-like headache developing during activity (LOE 
III; GOR B).
2. CT angiography is recommended to identify the existence 
of an aneurysm when an SAH is not identified on non-contrast 
CT, and lumbar puncture is recommended when diagnostic 
imaging with brain CT and CT angiography is vague (LOE III; 
GOR B).
3. When an SAH is diagnosed, DSA is recommended to es-
tablish an accurate treatment plan; however, recently developed 
multidetector CT angiography may be performed as a supple-
ment to the DSA or as an alternative in selected patients for 
whom DSA is not available (LOE III; GOR B).
4. A delayed repetitive DSA is recommended in patients with 
a diffuse SAH but no aneurysm detected on the initial CT angi-
ography and DSA (LOE III; GOR B).
INITIAL MANAGEMENT
Intensive care unit care
The aim of the initial management of patients with an aSAH 
is to prevent rebleeding, stabilize neurologic states and stop the 
case from worsening; hence, the intensive care unit (ICU), sub-
ICU or stroke unit are required.
Recommendations from foreign guidelines
JSSC (2008)57)
1. Expedient transfer to an appropriate referral center is rec-
ommended for patients first admitted to non-specialized facili-
ties. Appropriate control of blood pressure, analgesia, and se-
dation are necessary during the transfer, so patients should be 
transferred under the exclusive care of an accompanying physi-
cian, prepared to manage any change in their condition (grade B).
Evidence
It is reported that the prognosis of patients with aSAHs is bet-
ter when they are managed in high-volume centers214,289). The 
characteristics of these centers includes specialized neurologi-
cal ICU and an interdisciplinary team; thus, an exclusive team 
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with a specialized ICU is necessary for managing patients with 
aSAHs.
Recommendations
1. Patients with aSAHs are reasonable to be admitted to a 
specialized ICU or equivalent unit (LOE III; GOR B).
2. If a center does not have a specialized ICU, early transfer to 
a specialized center is recommended (LOE III; GOR B).
Bed rest
The most important thing to do before obliterating a rup-
tured aneurysm is to prevent rebleeding and to stabilize the pa-
tient’s neurologic status. Hence, patient activity restriction and 
bedrest may be required before treating an aneurysm.
Recommendations from foreign guidelines
ESO (2013)312)
1. To avoid situations that increase intracranial pressure, the 
patient should be kept in bed and the application of antiemetic 
drugs, laxatives, and analgesics should be considered before oc-
clusion of the aneurysm (good clinical practice [GCP]).
JSSC (2008)57)
1. Bedrest and avoidance of invasive tests or procedures im-
mediately after the onset of SAH is recommended (GOR B).
2. Bedrest only is not enough to prevent rebleeding after SAH 
compared to surgical or antihypertensive management (GOR B).
Evidence
There is no current evidence as to whether activity restriction 
and bedrest are required, which was also concluded from the Co-
chrane database system review in 2013. In the clinical guidelines 
and practice abroad, however, restriction of physical activity and 
continuous intensive care are recommended.
Recommendations
1. For patients with aSAHs, restriction of physical activity and 
bedrest are recommended prior to the obliteration of an aneu-
rysm (GCP).
Diet, antiemetics and laxatives
Patients with aSAHs usually present with nausea and vomit-
ing due to dural irritation and increased intracranial pressure. 
In addition, patients must fast before invasive examinations and 
the treatment of aneurysms under general anesthesia. Laxatives 
are not required when the treatment of aneurysms is immedi-
ately performed; however, laxatives may be required to relieve 
the digestive problems and likely prevent rebleeding when the 
treatment is delayed.
Recommendations from foreign guidelines
ESO (2013)312)
1. To avoid situations that increase intracranial pressure, the 
patient should be kept in bed and the application of antiemetic 
drugs, laxatives, and analgesics should be considered before 
occlusion of the aneurysm (GCP).
Evidence
There is no current evidence; however, a soft diet, antiemet-
ics, and laxatives have long been applied in the clinical setting.
Recommendations
1. Fasting is required, considering the possibility of aneurysm 
obliteration under general anesthesia or other surgical procedures 
(GCP).
2. Antiemetics and laxatives are required because nausea, 
vomiting or constipation may increase intracranial pressure and 
cause rebleeding (GCP).
Pain control
Patients with aSAHs usually present with severe headache 
due to dural irritation and increased intracranial pressure. An 
intense headache can increase blood pressure and intracranial 
pressure, so the headache should be controlled before treating 
the ruptured aneurysm. Non-steroidal anti-inflammatory drugs 
are widely used, and opioid analgesics are sometimes required 
for severe pain or when a sedative effect is required at the same 
time.
Recommendations from foreign guidelines
ESO (2013)312)
1. To avoid situations that increase intracranial pressure, the 
patient should be kept in bed and the application of antiemetic 
drugs, laxatives, and analgesics should be considered before 
occlusion of the aneurysm (GCP).
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JSSC (2008)57)
1. Adequate analgesia and sedation, as well as aggressive an-
tihypertensive treatment are necessary to prevent rebleeding 
(GOR A).
Evidence
Although there is no evidence regarding whether pain con-
trol is related to the prevention of rebleeding and prognosis of 
patients, it is considered clinically necessary.
Recommendations
1. Administration of analgesics should be considered when a 
headache is intolerable prior to treating an aneurysm (GCP).
Serum glucose control
An impairment in glucose metabolism occurs in approxi-
mately 1/3 of patients with aSAHs who have no previous histo-
ry of diabetes mellitus, which is known to be related to the prog-
nosis. Thus, initial management of hyperglycemia is required.
Recommendations from foreign guidelines
ESO (2013)312)
1. Hyperglycemia over 10 nmol/L (180 mg/dL) should be 
treated (GCP).
Evidence
Hyperglycemia in patients with aSAH is known to be related to 
patients’ initial states and long-term prognosis13,27,56,80,96,122,149,176,185,189,211). 
However, there is only one report that supports the relationship 
between intensive glucose control and an improved prognosis; 
moreover, hypoglycemia following the serum glucose control 
resulted in an increase in mortality28,186,232,323). In conclusion, the 
current evidence is considered insufficient.
Recommendations
1. Hyperglycemia over 200 mg/dL is reasonable to control, 
within the normal range not causing hypoglycemia (LOE IIb; 
GOR B).
Osmotic therapy
An initial increase in intracranial pressure after an aSAH re-
sults from the hemorrhage itself, brain edema, hydrocephalus 
and the initial brain insult. Increased intracranial pressure re-
sults in neurological deterioration and leads to increased mor-
bidity and mortality.
Recommendations from foreign guidelines
JSSC (2008)57)
1. Hyperosmotic diuretics are recommended for increased 
intracranial pressure (GOR C1).
Evidence
There are currently no data on the effect of mannitol on SAHs. 
However, there are a few reports on the effect and safety of hy-
pertonic saline. In patients with poor-grade aSAHs, bolus ad-
ministration of 7.2% or 23.5% saline resulted in the restoration 
of cerebral perfusion and clinical improvement3,26,326,327). How-
ever, it is difficult to conclude whether osmotic therapy is effec-
tive because there are only small numbers of reports of small-
sized cohort without comparison.
Recommendations
1. Osmotic therapy is recommended for patients whose neu-
rologic states are unstable due to increased intracranial pressure 
before treating a ruptured aneurysm (LOE IIa; GOR B).
Fever control
A fever is usually observed in 40–70% of patients with aSAHs, 
and a fever is more common in patients with large amount of SAH 
or IVH than in patients with only a little.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Aggressive control of fever to a target of normothermia by 
use of standard or advanced temperature modulating systems 
is reasonable in the acute phase of aSAH (class IIa; LOE B).
ESO (2013)312)
1. Increased temperature should be treated medically and 
physically (GCP).
Evidence
A fever is considered an independent prognostic factor of 
aSAHs; however, this is based on retrospective studies73,89,227,240), 
and there is no current prospective study on fever, infection, 
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neuronal damage and prognosis. Non-steroidal anti-inflamma-
tory drugs can be administered as a first-line treatment, and 
newly developed managements such as surface or endovascu-
lar targeted temperature management have been reported as 
more effective for fever control48,72). However, this kind of inten-
sive management easily causes complications such as shivering. 
Intensive fever control is not easy to recommend because it is 
unclear whether it helps improve the prognosis of patients with 
aSAHs.
Recommendations
1. A fever is usually observed in patients with aSAH and a fe-
ver is reasonable to be controlled with drugs if the fever persists 
(LOE III; GOR B).
2. Surface or endovascular targeted temperature manage-
ment can be recommended only for cases of increased intracra-
nial pressure or other definite indications (LOE III; GOR B).
PREVENTION OF REBLEEDING
Medical management
Rebleeding in patients with aSAHs is a major problem, resulting 
in fatal complications and extremely poor prognoses. Rebleeding 
most commonly develops within 2–12 hours from initial bleed-
ing, and most rebleeding occurs within 24 hours101,128,154,229,238). 
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Between the time of aSAH symptom onset and aneurysm 
obliteration, blood pressure should be controlled with a titrat-
able agent to balance the risk of stroke, hypertension-related 
rebleeding, and maintenance of cerebral perfusion pressure 
(class I; LOE B).
2. The magnitude of blood pressure control to reduce the risk 
of rebleeding has not been established, but a decrease in systolic 
blood pressure to <160 mmHg (class IIa; LOE C).
3. For patients with an unavoidable delay in obliteration of 
aneurysm, a significant risk of rebleeding, and no compelling 
medical contraindication, short term aminocaproic acid is rea-
sonable to reduce the risk of early aneurysm rebleeding (class 
IIa; LOE B).
ESO (2013)211)
1. Until coiling or clipping, systolic blood pressure should be 
kept below 180 mmHg; this may be already achieved by apply-
ing analgesics and nimodipine (GCP).
2. If systolic pressure remains high despite these treatments 
further lowering of blood pressure should be considered (LOE 
IV; level C).
3. If blood pressure is lowered the mean arterial pressure 
should be kept at least above 90 mmHg (GCP).
JSSC (2008)57)
1. Bedrest and avoidance of invasive tests or procedures im-
mediately after the onset of SAH is recommended (GOR B).
2. Adequate analgesia and sedation, as well as aggressive an-
tihypertensive treatment are necessary to prevent rebleeding 
(GOR A).
3. Careful prescription of antihypertensive agents is neces-
sary (GOR B).
4. Although antifibrinolytic agents tend to reduce the inci-
dence of rebleeding, an increased rate of cerebral ischemia in these 
patients offsets any improvement in overall outcome (GOR B).
5. Factors associated with the risk rebleeding in the acute state 
are the clinical status, presence of hypertension (systolic pres-
sure over 200 mmHg), cerebral angiography performed within 
6 hours of the initial bleeding, use of restraints during the ex-
aminations, intraventricular bleeding, intracerebral bleeding, 
presence of hydrocephalus, and ventricular drain placement 
(GOR B).
6. Factors associated with the risk of rebleeding in the chron-
ic stage (after 1 month) are the location of the aneurysm and the 
presence of hypertension (GOR B).
7. In cases of SAH caused by dissecting aneurysms, the out-
come does not differ between patients treated surgically and 
conservatively (GOR C1).
8. To reduce the incidence of intraoperative rupture, intention-
al hypotensive management is sometimes undertaken (GOR B).
Evidence
The various causes of rebleeding are as follows : intracerebral 
hemorrhage (ICH), IVH, hyperglycemia at admission, lower 
GCS and poorer initial Hunt-Hess grade, large aneurysm and 
blood pressure higher than 160 mmHg9,58,98,114,207). 
Antifibrinolytic agents can lower the risk of rebleeding by 
40%278). The short-term administration of antifibrinolytic agents 
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does not increase cerebral ischemic complications but decreas-
es the risk of rebleeding; however, there is no significant differ-
ence in the prognosis at 3 months16,99,310). Meanwhile, a recent 
prospective comparative study reported that the administra-
tion of ɛ-aminocaproic acid within 48 hours from the onset in-
creases the risk of deep venous thrombosis by 8.5 times93); ac-
cordingly, caution is required in administration.
Recommendations
1. A systolic blood pressure below 160 mmHg is recommend-
ed to be controlled until surgical clipping or endovascular coil-
ing is performed (LOE III; GOR B).
2. The target blood pressure for the prevention of rebleeding 
is not clearly established, however maintenance of mean arte-
rial pressure above 90 mmHg is considerable to maintain ce-
rebral perfusion pressure (GCP).
Timing of treatment
The natural clinical course of aSAH is very poor; thus, in-
tensive treatment is required. High-volume centers should al-
ways prepare for emergent situations because an aneurysm can 
rupture in anytime. However, it is not uncommon for immedi-
ate management to be difficult to start, depending on the inter-
nal situation of a center. One of the most important treatment 
processes is surgical clipping or endovascular coiling for the 
prevention of rebleeding, and the timing of treatment should be 
decided by taking factors related to the patients, the disease, and 
the hospital into account.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Surgical clipping or endovascular coiling of the ruptured 
aneurysm should be performed as early as feasible in the ma-
jority of patients to reduce the rate of rebleeding after aSAH 
(class I; LOE B).
ESO (2013)312)
1. Aneurysm should be treated as early as logistically and 
technically possible to reduce the risk of rebleeding; if possible 
it should be aimed to intervene at least within 72 hours after 
onset of first symptoms.
2. This decision should not depend on grading (LOE III; 
level C).
JSSC (2008)57)
1. Preventive measures against rebleeding are of utmost im-
portance (GOR A).
2. For cases rated as “not severe” (grades I–III according to 
the severity classification), early aneurysm treatment to prevent 
rebleeding (within 72 hours after the initial bleeding) is rec-
ommended, unless limited by age, presence of systemic com-
plications, other difficulties in treatment, etc. (GOR B).
3. For cases rated as “relatively severe” (grade IV according 
to the severity classification), the indications for preventive 
measures against rebleeding are determined based on factors 
such as the patient’s age and the aneurysm location (GOR C1). 
4. For the most severe cases (grade V according to the sever-
ity classification), preventive measures against rebleeding are 
principally not implemented in the acute stage. Nevertheless, 
surgery for severe cases performed in the acute stage has been 
reported, since the risk of rebleeding is obviously higher in se-
vere cases (WFNS grades IV and V), in comparison to the mild 
cases (GOR C1).
5. In cases rated as moderate or less severe, the incidence of 
cerebral vasospasm is lower and the outcome is reported to be 
better following early surgery (GORe A).
6. In cases of ruptured middle cerebral artery aneurysm as-
sociated with intracerebral hematoma, early surgery may yield 
better results (GOR B).
7. Recurrent hemorrhage on the day of initial ictus is frequent 
in patients with SAH due to dissection of the vertebral artery, 
and early surgery had found to improve the outcome (GOR B).
8. For patients admitted more than 72 hours after the initial 
bleeding, prevention measures against rebleeding should be 
considered after the period of delayed cerebral vasospasm (elec-
tive surgery) (GOR B).
9. The risk of both ischemic and hemorrhagic complications 
can be minimized if the surgery is undertaken promptly after 
the 10th day following the initial bleeding (GOR C1).
Evidence
In patients with aSAHs, there is a rebleeding risk of approxi-
mately 15% within a few hours from the initial bleeding238). The 
cumulative risk of rebleeding is approximately 40% after the 
first day, and the mortality rate is approximately 40%; thereaf-
ter, the rebleeding risk decreases at a rate of 3% per year beyond 
4 weeks from the initial bleeding127). Many other studies have 
reported that the rebleeding risk was the highest at the first 
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week and then rapidly decreased after 3 weeks from the initial 
bleeding124,154,351). Because rebleeding results in a high rate of 
mortality, the dominant opinion favors early treatment within 
3 days over the previously used method of delayed treatment 
beyond 7 days65,155). In addition, because the rebleeding risk is 
highest within the first 24 hours after the initial bleeding50,154), 
the number of centers that tend to perform extremely early treat-
ment, within the first 24 hours, is increasing; with this earlier 
treatment, satisfactory prognosis has been reported182,195,244,246). 
Moreover, the risk of delayed cerebral ischemia was lower in 
the early treatment group77).
Recommendations
1. It is reasonable to treat ruptured aneurysms within 72 
hours from the initial bleeding to prevent rebleeding if there are 
no obstacles to treatment (LOE IIa; GOR B).
Surgical clipping and endovascular coiling
Surgical clipping or endovascular coiling for the prevention 
of rebleeding is one of the most important treatment proce-
dures in patients with aSAH. It is reasonable to determine the 
treatment modalities considering patient-, disease- and facility-
related factors as well as the treatment results of an institution.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Complete obliteration of the aneurysm is recommended 
whenever possible (class I; LOE B).
2. Determination of aneurysm treatment, as judged by both 
experienced cerebrovascular surgeons and endovascular spe-
cialists, should be a multidisciplinary decision based on char-
acteristics of the patient and the aneurysm (class I; LOE C).
3. For patients with ruptured aneurysms judged to be tech-
nically amenable to both endovascular coiling and neurosur-
gical clipping, endovascular coiling should be considered (class 
I; LOE B).
4. In the absence of a compelling contraindication, patients 
who undergo coiling or clipping of a ruptured aneurysm should 
have delayed follow-up vascular imaging (timing and modality 
to be individualized), and strong consideration should be given 
to retreatment, either by repeat coiling or microsurgical clip-
ping, if there is a clinically significant (e.g., growing) remnant 
(class I; LOE B).
5. Microsurgical clipping may receive increased consider-
ation in patients presenting with large (>50 mL) intraparen-
chymal hematomas and middle cerebral artery aneurysms. 
Endovascular coiling may receive increased consideration in 
the elderly (>70 years of age), in those presenting with poor-
grade (WFNS classification IV/V) aSAH, and in those with an-
eurysms of the basilar apex (class IIb; LOE C).
6. Stenting of a ruptured aneurysm is associated with increased 
morbidity and mortality, and should only be considered when 
less risky options have been excluded (class III; LOE C).
ESO (2013)312)
1. The best mode of intervention should be discussed in an 
interdisciplinary dialogue between neurosurgery and neuro-
radiology.
2. Based on this discussion patients should be informed and 
included in the process of decision making whenever possible.
3. In cases where the aneurysm appears to be equally effec-
tively treated either by coiling or clipping, coiling is the pre-
ferred treatment (LOE I; level A).
4. In general, the decision on whether to clip or coil depends 
on several factors related to 3 major components :
1) Patient : age, comorbidity, presence of ICH, SAH grade, 
aneurysm size, location and configuration, as well as on status 
of collaterals (LOE III; level B).
2) Procedure : competence, technical skills and availability 
(LOE III; level B)
3) Logistics : the grade of interdisciplinarity (LOE III; level B)
In patients with aneurysmal SAH :
5. Factors in favour of operative intervention (clipping) are : 
younger age, presence of space occupying ICH (LOE II; level B), 
and aneurysm-specific factors such as :
- Location : middle cerebral artery and pericallosal aneu-
rysm (LOE III; level B)
- Wide aneurysm neck (LOE III; level B)
- Arterial branches exiting directly out of the aneurysmal 
sack (LOE III; level B)
- Other unfavourable vascular and aneurysmal configura-
tion for coiling (LOE IV; level C)
6. Factors in favour of endovascular intervention (coiling) 
are : age above 70 years, (LOE II; level B), space occupying ICH 
not present (LOE II; level B), and aneurysm-specific factors 
such as :
- Posterior location
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- Small aneurysm neck
- Unilobar shape (LOE III; level B) 
7. Elderly patients should not per se be excluded from treat-
ment; decisions whether or not to treat depend on the clinical 
and physical condition of the patients.
JSSC (2008)57)
1. Endovascular treatment should be considered as the pre-
ventive measure for rebleeding, in suitable patients with rup-
tured intracranial aneurysms (GOR B).
2. Endovascular treatment should be considered in cases 
where surgical treatment is difficult or the surgical/general an-
esthetic risk is high (GOR B).
3. Endovascular treatment may be advantageous in the man-
agement of patients with multiple aneurysms since all aneu-
rysms can be treated during a single treatment session (GOR 
C1).
4. Endovascular treatment is not suitable for broad-necked 
aneurysms or large/giant aneurysms, because of the high fre-
quency of incomplete obstruction or recanalization (GOR B).
5. Surgical treatment
1) Neck clipping is the method of choice for direct surgery of 
cerebral aneurysms (GOR A).
2) The incidence of rebleeding after coating or wrapping re-
mains higher than that after clipping, but lower than that in 
conservatively treated aneurysms (GOR A).
3) In some special cases where the aneurysm develops in the 
non-branching portion of the internal carotid artery (i.e., blis-
ter-like aneurysm), clipping on wrapping material is recom-
mended (GOR C1).
4) In cases with dissection of the vertebral artery, trapping, 
rather than proximal occlusion of the parent artery, is recom-
mended for prevention of rebleeding (GOR C1).
5) Direct surgical clipping of recurrent aneurysm after endo-
vascular coiling has been reported to be useful in some cases 
(GOR C1).
6) Careful monitoring of the occlusion time is necessary, 
particularly in severe cases and elderly patients (GOR B).
7) Monitoring of cerebral blood flow and oxygen saturation 
during occlusion has been reported as useful for preventing 
ischemic complications (GOR C1).
8) When the morphology of the aneurysm neck, the course 
of perforators, or the positioning the clip is difficult to confirm 
under the surgical microscope, neuroendoscopy or intraopera-
tive cerebral angiography has been reported to be useful (GOR 
C1).
9) If the occlusion test is positive, an arterial bypass should 
be performed before ligation of the parent artery (GOR B).
10) Combined treatment such as combination of endovas-
cular treatment (parent artery occlusion with a coil) and bypass 
surgery has also been reported to be useful (GOR C1).
11) Reduction of hydrocephalus is seen when intraoperative 
fenestration of the lamina terminalis is performed, intended to 
prevent secondary chronic hydrocephalus after SAH (GOR C1).
12) To reduce the incidence of intraoperative rupture, inten-
tional hypotensive management is sometimes undertaken 
(GOR B).
6. Endovascular treatment
1) For broad-necked aneurysms, a balloon catheter may be 
utilized to prevent coil protrusion, but has to be used with ex-
treme care during the acute stage (GOR C1).
2) The indications for intra-aneurysmal coil embolization 
are as follows : (1) aneurysm with narrow neck (less than 4–5 
mm), (2) small overall aneurysm size (less than 15 mm), and 
(3) a dome/neck ratio of more than 2 (GOR C1).
3) Recent introduction of coils with 3D structures and the 
development of neck remodeling technique using balloons have 
broadened the indications of coil embolization to include cases 
with a dome/neck ratio of less than 2 (GOR C1).
4) Even during the high risk period of vasospasm, it has been 
reported that embolization is possible if percutaneous angio-
plasty or vascular dilation is performed (GOR C1),
5) Early treatment with endovascular embolization after the 
initial bleeding is desirable (GOR B).
6) The incidence of cerebral vasospasm following endovas-
cular treatment has been reported to be lower or similar to that 
following clipping, whereas the incidence of cerebral infarction 
does not differ significantly, and the outcome is comparable 
between the two measures (GOR B).
7) The outcome of coil embolization is reported to be com-
parable to surgical treatment for aneurysms in the posterior cir-
culation (GOR B).
8) The treatment should be selected based on adequate indi-
vidual clinical assessment, for aneurysm of any location (GOR 
C1).
9) Anticoagulant/antiplatelet therapy for preventing periop-
erative embolic complication, due to thrombosis, is well-recog-
nized but yet to be accepted as a standard therapy (GOR C1).
J Korean Neurosurg Soc 61 | March 2018
140 https://doi.org/10.3340/jkns.2017.0404.005
10) Anticoagulant/antiplatelet therapy is common in the 
management of ruptured cerebral aneurysm in the chronic stage 
(GOR C1). 
11) Transcranial Doppler ultrasonography is occasionally 
used for intraoperative emboli detection (GOR C1).
12) Fibrinolytic therapy in the acute stage of a ruptured an-
eurysm should be applied carefully, because it may lead to re-
rupture of aneurysm (GOR C1).
13) Embolization of ruptured aneurysm in the acute stage 
must be performed with extreme caution (GOR B).
14) Appropriate follow-up neuroimaging study of the treat-
ed aneurysms is therefore considered mandatory (GOR B).
15) Progression of thrombosis, recanalization, and some-
times rebleeding are not uncommon. Periodic surveillance is 
therefore necessary after coil embolization (GOR A).
16) The capability of MRA to identify residual aneurysm 
neck smaller than 3 mm is inferior to DSA, thus, follow-up im-
aging should be customized individually (GOR C1).
17) Additional treatment with endovascular or open surgery 
should be considered in patients with recanalized aneurysms, 
if necessary (GOR A).
18) Parent artery occlusion is indicated for internal carotid 
artery aneurysms, vertebral artery aneurysms, and dissecting 
aneurysms (GOR C1).
19) The necessity of parent artery occlusion should be care-
fully assessed individually, since it is difficult in the acute stage 
(GOR C1).
20) A bypass should be considered in patients who do not 
tolerate well the test occlusion (GOR C1).
Evidence
Since the introduction of Guglielmi detachable coils in 1991, 
endovascular coiling has become one of the major treatment 
modalities for cerebral aneurysms. There have also been im-
provements in the treatment results from surgical clipping, us-
ing intraoperative monitoring317) and intraoperative fluorescent 
angiography275), among other methods. There have been stud-
ies comparing endovascular coiling and surgical clipping in pa-
tients with aSAHs168,210,219,221,222,309). In the first prospective and 
randomized study of a single center, Koivisto et al.168) reported 
that there was no difference in clinical outcomes between endo-
vascular coiling and surgical clipping. A multicenter, prospec-
tive and randomized study, named International Subarachnoid 
Aneurysm Trial (ISAT), first reported in 2002 that morbidity 
and mortality at one year were significantly lower in the coiling 
group than in the clipping group (23.7% vs. 30.6%, respective-
ly, p=0.0019)219). Other mid-term results of the ISAT were pub-
lished in 2005 and showed that morbidity and mortality were 
lower in the coiling group than in the clipping group (23.5% vs. 
30.9%, p=0.0001)222). However, the ratio of independent survi-
vors did not differ between the two groups (82% in the clipping 
group vs. 83% in the coiling group)221). The third representative 
study (the Barrow Ruptured Aneurysm Trial) showed that the 
coiling group achieved better 1-year clinical outcomes than 
did the clipping group; however, there was no difference in the 
3-year clinical outcomes between the groups211,309). According 
to a meta-analysis of the former three main studies, the neuro-
logic outcome was better in the coiling group after one year 
but was not different after three years237). In summary, endovas-
cular coiling is considered first when both surgical clipping and 
simple endovascular coiling are available for the treatment of 
patients with aSAHs; however, the final selection of treatment 
modality depends on the performance of the center.
There are conflicting results reported for the durability of a 
certain modality. In the 2005 ISAT222), the rebleeding rate one 
year after the initial treatment was 0.06% in the clipping group 
and 0.2% in the coiling group. Mitchell et al.218) reported long-
term follow-up results based on the ISAT database indicating 
that the rebleeding rate was 0.032%/person-year in the clipping 
group and 0.24%/person-year in the coiling group; the rate in 
the coiling group is 8 times higher than that in the clipping group. 
The retreatment rate for recurrent aneurysms was lower in the 
clipping group (3.8% in the clipping group vs. 17.4% in the coil-
ing group), and the late retreatment rate was 6.9 times higher in 
the coiling group46). Younger age, larger-sized aneurysms and 
incomplete obliteration were considered as the risk factors of 
late retreatment. A recent 18-year follow-up of the British pop-
ulation in the ISAT database showed that the coiling group had 
a higher rate of functional independence but also a higher re-
bleeding rate220). In a systematic review and meta-analysis191), the 
rebleeding rate was higher in the coiling group. Thus, follow-up 
imaging should be performed in the patients treated with endo-
vascular coiling as well as in those treated with surgical clip-
ping, although the clipping group has a lower risk of rebleeding.
As mentioned before, age is an important factor in selecting 
a treatment modality. In the ISAT, endovascular coiling usually 
shows better short-term clinical outcomes and lower durability 
compared to surgical clipping. According to a study correcting 
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the different rebleeding rates between the coiling and clipping 
groups, the rate of poor prognosis was higher by 10.1% for those 
older than 50 years and 3% for those younger than 50 years in 
the clipping group. However, there was no benefit of coiling on 
the good prognosis for patients younger than 40 years because 
the rebleeding rate and prognosis offset each other191). 
When cranial nerve palsy developed by compression of the 
aneurysm, a rapid decompression seems to be advantageous for 
the recovery from cerebral nerve palsy. In a systemic review295), 
the clipping group showed a significantly higher improvement 
rate of visual symptoms than did the coiling group (OR 2.9, 95% 
CI 1.5–6.0, p=0.002), and surgical clipping was the only pre-
dictive factor of visual improvement in a multivariate analysis. 
There were also similar results in cases of oculomotor palsy by 
posterior communicating artery aneurysms. A single-center study 
reported similar improvement rates in both groups248); howev-
er, several meta-analysis studies showed a higher improvement 
rate in the clipping group than in the coiling group115,159). In a sys-
tematic review159), complete recovery from oculomotor palsy was 
significantly higher in the clipping group than in the coiling 
group (55% vs. 32%; OR 2.6, 95% CI 1.3–5.1, p=0.006), and 
partial recovery was also higher in the clipping group than in the 
coiling group (92% vs. 74%; OR 4.3, 95% CI 1.8–10.4, p=0.001). 
In a meta-analysis159), the recovery rate from oculomotor palsy 
was significantly higher in the clipping group than in the coil-
ing group (83.7% vs. 52.7%; OR 6.04, 95% CI 1.88–19.45, p= 
0.003), and the preoperative degree of oculomotor palsy (OR 
0.07, 95% CI 0.02–0.28, p=0.001) and surgical clipping (OR 
6.37, 95% CI 1.73–23.42, p=0.005) were the factors for complete 
recovery from oculomotor palsy in the multivariate analysis.
In selecting treatment modalities for the cerebral aneurysms, 
whether space-occupying lesion such as hematoma exist is very 
important. It is generally agreed that surgical clipping is better 
than coiling when ICH is combined108,125,158). 
The location and shape are also important factors in the se-
lection of treatment modalities for cerebral aneurysms. Surgi-
cal clipping can be considered first in cases of wide-necked an-
eurysms, large or giant aneurysms, aneurysms in the middle 
cerebral artery and aneurysms from which arterial branches 
arise108,109,120,125,260,270).
In contrast, endovascular coiling is considered first in cases 
that are difficult to treat with surgical clipping or have a high 
risk of requiring surgery and general anesthesia85,109,209). Accord-
ing to an ISAT subgroup analysis of old patients, the coiling 
group showed a better prognosis; however, surgical clipping 
was superior in treating middle cerebral artery aneurysms284). 
Endovascular coiling is not easy for middle cerebral artery an-
eurysms because the aneurysms generally have a wide neck 
and arterial branches. If an aneurysm has a narrow neck and no 
branching arteries, endovascular coiling can be sufficiently ef-
fective. There is still some debate around the selection of a treat-
ment modality; however, endovascular coiling is likely better 
for patients with a medically poor status, especially for older 
aged patients256,320,334) and those in which a vasospasm is iden-
tified37,334). 
It is generally accepted that endovascular coiling is better in 
treating posterior circulation aneurysms. According to a meta-
analysis of endovascular coiling of basilar bifurcation aneu-
rysms, the mortality and permanent morbidity were 0.9% and 
5.4%, respectively38). In a comparative study of basilar top aneu-
rysms, the rate of poor prognosis was lower in the coiling group 
than in the clipping group (11% vs. 30%)197). There was no sig-
nificant difference between both groups in treating paraclinoid 
aneurysms14,132). 
When multiple aneurysms are identified in a patient with 
aSAH, simultaneous treatment, if possible, can decrease the se-
lection error of the ruptured aneurysm and prevent rebleeding 
from occurring. Endovascular coiling can treat most of the si-
multaneously identified aneurysms with an acceptable com-
plication rate285,300). 
It has been reported that there is no difference in the safety 
of balloon-assisted coil embolization and simple coil emboliza-
tion252). Some reports indicate that balloon-assisted coiling in-
creases the risk of intraprocedural aneurysm rupture, while 
others indicate that the balloon can help to immediately arrest 
bleeding253). In contrast, the success rate for stent-assisted coil 
embolization is technically higher, but the rate of complications 
such as thromboembolism is also higher. Thus, it would be rea-
sonable to limit the use of stents for ruptured aneurysms30).
In conclusion, endovascular coiling is advantageous for short-
term treatment results, but disadvantageous for long-term du-
rability. Thus, coiling is not the primary treatment option for 
every aSAH but is one rational treatment modality for selected 
patients. In addition, there are several factors to consider in the 
selection of optimal treatment modalities; the individual per-
forming a certain treatment modality can be more important 
than the type of treatment performed (coiling or clipping).
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Recommendations
1. Treatment modalities for ruptured aneurysms should be 
selected based on a discussion between cerebrovascular sur-
geons and endovascular interventionists, considering patient-, 
aneurysm- and institution-related factors (GCP).
2. When both surgical clipping and endovascular coiling are 
available, endovascular coiling is recommended to be consid-
ered first (LOE Ib; GOR A). Moreover, the clinical perfor-
mance of the centers should be considered, and a stent should 
be carefully used in limited cases where there is no alternative 
treatment method (LOE III; GOR B).
3. Surgical clipping is recommended to be considered first in 
the following situations :
1) Age younger than 40 years (LOE IIa; GOR B).
2) Space-occupying hematoma requiring removal and de-
compression (LOE III; GOR B).
3) Aneurysm factors :
- Middle cerebral artery aneurysms (LOE IIa; GOR B).
- Wide-necked aneurysms (LOE III; GOR B).
- Aneurysms from which branches arise (LOE III; GOR B).
4. Endovascular coiling is recommended to be considered 
first in the following situations :
1) Age older than 70 years (LOE IIa; GOR B).
2) Patients with a poor neurological status such as WFNS 
grades IV and V (LOE III; GOR B).
3) Aneurysm factors :
- Posterior circulation aneurysms (LOE IIa; GOR B).
- Narrow-necked aneurysms (LOE III; GOR B)
5. A long-term follow-up after treatment is recommended, 
especially in cases treated with endovascular coiling because 
of the possibility of recanalization (LOE IIb; GOR B).
Anesthesia management during surgical or 
endovascular intervention
Anesthesia is critical in treating ruptured cerebral aneurysm 
in patients, and monitoring and maintaining appropriate 
blood pressure and blood sugar levels as well as body tempera-
ture is important for producing good treatment outcomes and 
improving prognoses.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Minimization of the degree and duration of intraoperative 
hypotension during aneurysm surgery is probably indicated 
(class IIa; LOE B).
2. There are insufficient data on pharmacological strategies 
and induced hypertension during temporary vessel occlusion to 
make specific recommendations, but there are instances when 
their use may be considered reasonable (class IIb; LOE C).
3. Induced hypothermia during aneurysm surgery is not rou-
tinely recommended but may be a reasonable option in select-
ed cases (class III; LOE B).
4. Prevention of intraoperative hyperglycemia during aneu-
rysm surgery is probably indicated (class IIa; LOE B).
5. The use of general anesthesia during endovascular treat-
ment of ruptured cerebral aneurysms can be beneficial in se-
lected patients (class IIa; LOE C).
Evidence
In the past, hypotension was induced to prevent intraopera-
tive rebleeding of aneurysms86,102,130). However, the induction of 
excessive hypotension (systolic blood pressure <60 mmHg) has 
the potential risk of causing neurological impairment due to 
early or chronic ischemic injury51,130), while high intraoperative 
systolic blood pressure is a risk factor for poor prognosis. It has 
been reported that adequate management of intraoperative 
blood pressure is associated with favorable short-term clinical 
outcomes94). A subsequent study reported that a decrease in the 
mean arterial pressure by more than 50% is associated with 
poor prognosis; however, the association was statistically in-
significant after adjusting for age and preoperative neurologi-
cal grade131). Maintaining hypertension could be considered in 
cases predicted to require a temporary clipping in the parent 
vessel for more than two minutes; however, further studies are 
needed to validate this consideration.
Patients with brain damage, including those with aSAHs, 
commonly have hyperglycemia in relation to glucose metabo-
lism. Hyperglycemia is also associated with the initial clinical 
grade or severity at the time the patient presents at a hospi-
tal4,80) and has an independent causal relationship with poor 
prognostic factors80,149,185,211,273,345). It has been suggested that 
continuous intraoperative hyperglycemia is associated with a 
long-term decline in cognitive and neurological functions247) 
and that postoperative glycemic control reduces the incidence 
of postoperative infections28). However, it is unclear whether 
aggressive correction of hyperglycemia has a beneficial effect 
on prognosis.
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In a multicenter, randomized study of the induction of hy-
pothermia (33°C) during ruptured cerebral aneurysm surgery, 
hypothermia was relatively safe but not beneficial for improv-
ing mortality or the neurological outcomes of patients with rel-
atively good grade conditions early on8,324). Although induced 
hypothermia did not result in higher incidences of cardiovas-
cular diseases236), it was not helpful for the short- and long-term 
prognoses in cases that required temporary clipping during 
surgery129). Nevertheless, hypothermia is speculated to be use-
ful in selected cases, and there are no studies that examined its 
effects in poor grade patients.
A method involving deep hypothermia with cardiac arrest 
under extracorporeal circulation during a complex aneurysm 
surgery has been reported; however, outcome data are lacking, 
as most existing data were presented as case reports190,292,293,307,308). 
Some studies reported that inducing cardiac arrest for less than 
30 minutes in patients younger than 60 years safely leads to good 
prognosis203).
There have been reports about using adenosine-induced tem-
porary cardiac arrest to repair an aneurysm that ruptured intra-
operatively or to decompress a giant aneurysm22,24,25,113,160,196,255); 
however, further controlled trials are needed to verify this. 
Nevertheless, it has been reported that in some limited cases, 
the use of adenosine does not increase the prevalence of cardi-
ac complications or mortality22,25,160).
In general, the anesthetic principles applied in a craniotomy 
can be applied in endovascular treatment. Methods of anesthe-
sia for endovascular treatment differ at each institution; howev-
er, sedation or general anesthesia is the typical choice141,183,205,257,336). 
There are no existing studies comparing the two methods; 
however, sedation is useful for confirming neurological symp-
toms and causes little change in blood pressure67,153,336). Prefer-
ence for general anesthesia over sedation has been growing, as 
general anesthesia minimizes patient movement, which en-
hances the quality of images used for therapy67,336).
Recommendations
1. Adequate blood pressure management is recommended 
during the surgery of ruptured cerebral aneurysms, and avoid-
ing excessive hypotension is desirable (LOE III; GOR B). 
2. Hyperglycemia need to be treated during the surgery of 
ruptured cerebral aneurysms, and adequate glycemic control 
is desirable (LOE IIa; GOR B).
3. Induced hypothermia is not recommended during the sur-
gery of ruptured cerebral aneurysms in patients with good pre-
operative neurological status (LOE Ib; GOR A).
MANAGEMENT OF DELAYED CEREBRAL ISCH-
EMIA AND VASOSPASM
Cerebral vasospasm usually occurs between 7–10 days from 
the onset of an aSAH and spontaneously resolves after 21 days. 
Vasospasm develops as cerebral vessels come in contact with 
oxyhemoglobin. Despite extensive research on this mechanism, 
no effective prophylactic therapy has been introduced; one rea-
son may be that vasospasm occurs at multiple levels, spanning 
both larger and smaller vessels. In cases where arterial narrow-
ing is angiographically documented, delayed cerebral ischemia 
or infarction may be defined as neurological deficits such as 
hemiparesis, aphasia, apraxia, hemianopia and neglect, with-
out a particular cause340). For relatively large blood vessels, only 
approximately 50% of cases of vasospasm show neurological 
symptoms even when vasospasms are angiographically con-
firmed. The severity of vasospasm is associated with symptoms; 
however, patients with severe vasospasm may be asymptomat-
ic, while those with moderate spasms may not only present 
symptoms but also develop cerebral infarction1). The onset of 
cerebral ischemia and infarction is speculated to be multifacto-
rial, involving distal microcirculatory failure, reduced collater-
al circulation, and genetic or physiological variations in cellular 
tolerance to ischemia318,354). Delayed cerebral ischemia (DCI), 
which is related to cerebral vasospasm, is a major cause of the 
morbidity and mortality associated with aSAHs, and treatment 
for the condition is complex. There have been significant ad-
vances to the previous guidelines for oral nimodipine, eu-
volemia maintenance, Triple H therapy, and endovascular 
therapy using vasodilators or balloons.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Oral nimodipine should be administered to all patients 
with aSAH (class I; LOE A). 
2. Maintenance of euvolemia and normal circulating blood 
volume is recommended to prevent DCI (class I; LOE B). 
3. Prophylactic hypervolemia or balloon angioplasty before 
the development of angiographic spasm is not recommended 
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(class III; LOE B).
4. Transcranial Doppler is reasonable to monitor for the de-
velopment of arterial vasospasm (class IIa; LOE B).
5. Perfusion imaging with CT or magnetic resonance can be 
useful to identify regions of potential brain ischemia (class IIa; 
LOE B).
6. Induction of hypertension is recommended for patients 
with DCI unless blood pressure is elevated at baseline or car-
diac status precludes it (class I; LOE B). 
7. Cerebral angioplasty and/or selective intra-arterial vasodi-
lator therapy is reasonable in patients with symptomatic cere-
bral vasospasm, particularly those who are not rapidly respond-
ing to hypertensive therapy (class IIa; LOE B).
ESO (2013)312)
1. Nimodipine should be administered orally (60 mg/4 h) to 
prevent delayed ischaemic events (LOE I, level A).
2. In case oral administration is not possible nimodipine 
should be applied intravenously (GCP).
3. Magnesium sulphate is not recommended for the preven-
tion of DCI (LOE I; level A).
4. There is no evidence from controlled studies for induced 
hypertension or hypervolaemia to improve outcome in pa-
tients with delayed ischaemic deficit (LOE IV; level C).
JSSC (2008)57)
1. Diagnosis of cerebral vasospasm
1) Usually, the definitive diagnosis of cerebral vasospasm is 
based on the angiographical findings. Transcranial Doppler 
ultrasonography is also useful as a noninvasive auxiliary test 
(GOR B).
2) Other modalities such as MRA, diffusion-weighted MRI, 
3D-CTA, and single photon emission computed tomography 
have been advantageous in guiding management and may be 
complementary, though, there are insufficient data to date to 
recommend any of these techniques (GOR C1).
2. Treatment of cerebral vasospasm
1) Removal of subarachnoid hematoma : intrathecal fibrino-
lytic therapy using tissue plasminogen activator, and cisternal 
irrigation therapy using urokinase are useful in the prevention 
of vasospasm after aneurysmal SAH1 (GOR B).
2) Pharmacotherapy of cerebral vasospasm : systemic ad-
ministration of fasudil hydrochloride (Rho kinase inhibitor) have 
been shown to be effective in reducing vasospasm (GOR B).
3) Some investigators have reported the effectiveness of ni-
modipine, a calcium channel antagonist not yet approved in Ja-
pan, although no other calcium channel inhibitors have been 
shown to be effective (GOR C1).
4) Systemic hemodynamic therapy : induced hypertension, 
hypervolemia, and hemodilution (triple H therapy) are report-
ed to be effective at improving cerebral blood flow in the areas 
perfused by the vasospastic vessels (GOR B).
5) Although it appears relatively certain that triple H thera-
py can be useful in reversing deficits once they occur, the data 
supporting the finding that prophylactic hyperdynamic lessens 
the incidence of symptomatic spasm are considerably weaker 
(GOR B).
6) Hyperdynamic therapy, i.e., maintenance of cerebral cir-
culation with cardiac inotropic regulation under normovole-
mia, has also been attempted (GOR C1).
7) Intra-arterial papaverine is effective in reversal of spastic 
cerebral vessels (grade C1), but papaverine is short-acting and 
repeated treatment is necessary.
8) Although intra-arterial or intravenous administration of 
milrinone or intra-arterial fasudil hydrochloride have been re-
ported with excellent anecdotal results (GOR C1), their utility 
is not yet established.
9) PTA mechanically dilates the spastic cerebral vessels to 
result in improvement of cerebral blood flow and subsequent 
clinical symptoms (GOR C1). 
10) Although it is more effective and the effect lasts longer 
than intra-arterial papaverine infusion, it should be noted that 
there are still significant risks associated with PTA (GOR C1).
Evidence
DCI occasionally poses diagnostic challenges. Performing 
multiple neurological examinations is important; however, pa-
tients with poor clinical grade show reduced sensitivity to such 
tests. Hence, diagnostic approaches should be tailored to the 
particular clinical situation at hand. Several methods are used 
to diagnose arterial narrowing, perfusion abnormalities, or re-
duced cerebral oxygenation, and each method has both pros 
and cons. A study was conducted that compared the diagnosis 
of basilar arterial narrowing using various methods, but no 
randomized study comparing the different methods of diag-
nosis for predicting prognosis was performed. Some recent 
studies have shed light on a new perfusion imaging technique 
that reveals low perfusion areas by more accurately diagnosing 
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DCI compared to imaging techniques that show arterial nar-
rowing (CT angiography and DSA) and transcranial Doppler, 
which is useful for detecting changes in perfusions in the 
middle cerebral artery61,62,142,217,332,348). Despite the limitations of 
repeated examinations due to the use of contrasts and radia-
tion doses, perfusion CT is still a useful diagnostic method332). 
Meanwhile, a study also reported a method using quantitative 
electroencephalography for the early prediction of DCI106).
Most guidelines recommend nimodipine, whose efficacy has 
been well documented5,251). Although the efficacy of nimodip-
ine is statistically sound, it has only been verified in one rela-
tively large-scale study251). In a Cochrane review, a pooled anal-
ysis of 16 studies showed that the risk of mortality or severe 
morbidity associated with the use of calcium channel blockers 
was 0.81 (95% CI 0.72–0.92), and the number of treated patients 
needed to prevent one adverse outcome was 19 (95% CI 1–51)175). 
The RR of oral nimodipine was statistically significant (0.67, 
95% CI 0.55–0.81); however, the RRs of other calcium channel 
blockers or of intravenous nimodipine were not statistically 
significant. Oral administration of 60 mg of nimodipine in 
4-hour intervals for three weeks is usually considered the stan-
dard therapy, and patients with swallowing difficulties are rec-
ommended to take the drug in powder form. In a prospective 
randomized study, intravenous nimodipine was found not to 
differ from oral agents in the prevention of DCI and vasospasm, 
validating its use as an alternative in cases where administering 
oral agents is a challenge175).
The postoperative application of calcium channel blockers in 
the subarachnoid space has been attempted and shown to be 
effective; however, larger studies are needed to substantiate this 
finding19,156). One study has reported that antiplatelet drugs have 
limited contributions to reducing morbidity78). There are con-
tinuing efforts to prevent the development of cerebral vaso-
spasm and ischemic complications based on numerous studies, 
shedding light on the decisive roles for endothelial dysfunction 
at the microcirculatory level202). Some clinical trials have inves-
tigated the efficacy of statin, endothelin-1 antagonists, and 
magnesium sulfate259). Three randomized trials (two using 80 
mg of simvastatin and one using 40 mg of pravastatin) have 
verified the efficacy of statin; however, a meta-analysis and a 
recent randomized controlled trial did not support its utili-
ty164,339,352).
In a phase IIb clinical trial (Clazosentan to Overcome Neuro-
logical iSchemia and Infarct OccUrring after Subarachnoid 
hemorrhage [CONSCIOUS-1]), clazosentan, an endothelin-1 an-
tagonist, was found to be associated with a dose-dependent re-
duction of angiographic vasospasm201). The effects of clazosen-
tan on the clinical prognosis was initially unclear; however, 
clazosentan was suggested to be effective when precisely used 
for vasospasm-related infarction. However, subsequent studies 
(CONSCIOUS-2 and 3) failed to confirm its effectiveness in 
improving the clinical outcomes of patients who underwent ce-
rebral aneurysm clipping199,200,343). In a meta-analysis, although 
clazosentan significantly reduced the incidence of vasospasm-
related DCI and infarction, it did not improve prognosis299,338,343).
There have been several prior studies on magnesium sulfate. 
Although some studies have suggested magnesium sulfate to 
be associated with a reduction in delayed ischemic complica-
tions79), this effect was not supported by a meta-analysis76,355). A 
phase III trial (Intravenous Magnesium sulfate for Aneurysmal 
Subarachnoid Hemorrhage [IMASH]) did not confirm the 
clinical efficacy of magnesium sulfate compared to a placebo353). 
A subsequent trial (MASH-2) that compared intravenous infu-
sion of magnesium sulfate and placebo in patients with aSAH 
also found that magnesium did not result in better outcomes76). 
Several meta-analyses have also failed to support the efficacy 
of magnesium105,269). However, a study involving direct infusion 
of magnesium into the subarachnoid space is underway, in 
light of the fact that intravenous infusions are unable to effec-
tively increase the concentration of the agent in cerebrospinal 
fluid319).
Lumbar drainage has been noted in a case-control study to 
have beneficial effects166); however, a prospective, randomized 
comparative study has suggested that lumbar drainage only 
has beneficial effects on early outcomes and on reducing de-
layed ischemia, with no effects on improving outcomes after six 
months6). Hence, it is difficult to draw conclusions from these 
studies, and new prospective studies are ongoing (ClinicalTri-
als.gov, identifier : NCT01258257).
A meta-analysis of five studies showed that intrathecal throm-
bolytic infusion was effective to some extent172), and other stud-
ies have also reported intraventricular infusion to reduce va-
sospasm20,174).
The initial treatment of DCI involves hemodynamic aug-
mentation. Since hemodynamic augmentation was first intro-
duced in an observational study170), subsequent case studies 
and observational studies were conducted on induced hyper-
tension and hypervolemia, both of which were shown to be ef-
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fective in improving patients’ conditions. The risk associated 
with intentionally increasing arterial pressure and plasma vol-
ume include increased cerebral edema, bleeding at the infarc-
tion site7), reversible leukoencephalopathy344), myocardial in-
farction, and congestive heart failure. Although there were no 
comparative studies, the efficacy of this treatment is self-explan-
atory : most patients who undergo this treatment show improve-
ments, and the improvements deteriorate when the treatment 
is withdrawn early. However, the exact mechanism of the effect 
remains unclear. In some patients, an increase in the mean ar-
terial pressure under reduced autoregulation increases plasma 
volume, while some patients show arterial dilation caused by a 
direct rise in the intravascular pressure266). Conventionally, he-
modynamic augmentation therapy comprises hemodilution, 
hypervolemia, and hypertensive therapy; however, recent stud-
ies have noted a shift from this triple H therapy to the mainte-
nance of euvolemia and induced hypertension63,138,315). In con-
trast, a recent study has suggested that induced hypertension 
has low efficacy, calling for larger studies to validate the use of 
this therapy100,325). Another effective attempt implemented the 
use of aortic balloon devices10).
Endovascular therapy may be employed in cases where he-
modynamic augmentation fails to improve the patient’s condi-
tions or where the causative vascular abnormality is angio-
graphically documented143). This therapy involves angioplasty 
using balloons in accessible regions and the use of vasodilators 
for distal vessels. Although balloon angioplasty is associated 
with problems such as rupturing of blood vessels, thromboem-
bolism, and delayed stenosis, it is still useful in recurrent cases 
or cases that are nonresponsive to other treatments287,321). Pro-
phylactic balloon angioplasty was effective in reducing thera-
peutic angioplasty but did not improve clinical outcomes356). Var-
ious types of vasodilators are used, most of which are calcium 
channel blockers such as nimodipine, verapamil and nicardip-
ine, and some of which are nitric oxide donors298). Papaverine 
is becoming less popular due to its neurotoxicity305). One down-
side of vasodilators is their short-lasting effects. Although there 
has not been a randomized comparative study on vasodilators, 
many case reports have showed angiographic and clinical im-
provements1). A randomized comparative trial is underway to 
examine the outcomes of endovascular therapy using various 
pharmacological agents (ClinicalTrials.gov, identifier : NCT 
01996436).
Recommendations
1. Transcranial Doppler is useful in the diagnosis of vaso-
spasm-induced DCI; CT angiography and DSA, as well as per-
fusion CT are recommended (LOE III; GOR B).
2. Oral nimodipines should be used to prevent DCI (LOE Ia; 
GOR A). In cases where oral nimodipine use is not feasible, in-
travenous nimodipine can be recommended as an alternative 
(LOE IIa; GOR B).
3. Lumbar drainage should be performed for the prevention 
of DCI (LOE Ib; GOR A).
4. Prophylactic triple H therapy is not recommended for the 
prevention of vasospasm-induced DCI; however, maintaining 
euvolemia is recommended (LOE IIa; GOR B). 
5. After the onset of DCI, induced hypertension in accor-
dance with the patient’s neurological status is recommended 
(LOE IIa; GOR B).
6. For DCI that is nonresponsive to other treatments and re-
current DCI, intravenous infusions of pharmacological agents 
or balloon angioplasty can be recommended (LOE III; GOR B).
MANAGEMENT OF HYDROCEPHALUS
Hydrocephalus commonly follows the rupture of a cerebral 
aneurysm. As hydrocephalus is associated with poor outcomes, 
therapeutic intervention for acute or chronic symptomatic hy-
drocephalus is highly important.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. aSAH-associated acute symptomatic hydrocephalus should 
be managed by cerebrospinal fluid diversion (external ventric-
ular drainage [EVD] or lumbar drainage, depending on the 
clinical scenario) (class I; LOE B).
2. aSAH-associated chronic symptomatic hydrocephalus 
should be treated with permanent cerebrospinal fluid diversion 
(class I; LOE C).
3. Weaning EVD over >24 hours does not appear to be effec-
tive in reducing the need for ventricular shunting (class III; 
LOE B).
4. Routine fenestration of the lamina terminalis is not useful 
for reducing the rate of shunt-dependent hydrocephalus and 
therefore should not be routinely performed (class III; LOE B).
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ESO (2013)312)
1. In patients with CT-proven hydrocephalus and the third or 
fourth ventricle filled with blood, an external ventricular drain 
should be applied; this drain can be used to reduce and moni-
tor pressure and to remove blood; for this last reason the level 
of evidence is low (GCP).
2. In patients who are not sedated and who deteriorate from 
acute hydrocephalus, lumbar puncture might be considered if 
the third and fourth ventricle are not filled with blood and su-
pratentorial herniation is prevented (LOE IV; level C).
3. In patients who are sedated and have CT-proven hydro-
cephalus, lumbar drainage should be considered if the third and 
fourth ventricles are not filled with blood (LOE IV; level C).
4. Patients with symptomatic chronic hydrocephalus require 
ventriculo-peritoneal or ventriculo-atrial shunting (GCP).
JSSC (2008)57)
1. Cerebrospinal fluid drainage is performed, if necessary. In 
the acute stage of ruptured aneurysm, intracerebral hemorrhage 
has been reported as a potential complication of ventricular 
drainage following endovascular treatment. Particular care is 
needed especially when anticoagulants/antiplatelet agents are 
used (GOR C).
Evidence
Acute and chronic hydrocephalus develops in approximately 
20% and 10% of patients with aSAHs, respectively126). Patients 
who develop acute hydrocephalus may show ventricular en-
largement and poor neurological findings on brain CT. The 
onset of acute hydrocephalus has been reported to be associat-
ed more with the volume of intraventricular hemorrhage than 
with aSAHs12,126).
Acute hydrocephalus is treated with extraventricular drain-
age (EVD) or lumbar drainage, and neurological improvements 
are observed in EVD-treated patients with hydrocephalus118,216,263,264). 
Research data on the effect of EVD are heterogeneous : some 
studies suggested that EVD increases the risk of rebleeding or 
inflammation36,245), while others did not find heightened risks 
associated with EVD123,212).
In acute symptomatic hydrocephalus, EVD is chosen for pa-
tients with obstructive hydrocephalus accompanied by IVH in 
the third or fourth ventricles, whereas lumbar drainage is per-
formed for those with communicating hydrocephalus without 
IVH in the third or fourth ventricles and without a possibility 
of supratentorial herniation. However, clinical trials to support 
these conventional choices are lacking136,137).
Chronic hydrocephalus, which is characterized by neurolog-
ical symptoms such as dementia, gait disturbance, and urinary 
incontinence, is treated with a ventriculo-peritoneal shunt, 
which is effective in improving the symptoms330,335,341).
There are many ongoing studies attempting to elucidate the 
predictors of chronic hydrocephalus requiring shunt place-
ment. According to a study examining the effects of the persis-
tence of EVD performed in acute hydrocephalus on the inci-
dence of chronic shunt-dependent hydrocephalus, there was 
no significant difference in the incidence of chronic hydroceph-
alus between the rapid EVD weaning group (<24 hours) and 
slow EVD weaning group (96 hours) (63.4% vs. 62.5%)167). 
Among the studies that investigated the incidence of chronic 
shunt-dependent hydrocephalus in the surgical clipping group 
and coil embolization group, only one study suggested coil em-
bolization as a considerably higher risk factor than clipping66), 
whereas the remaining studies suggested that the two groups 
do not significantly differ in the incidence of shunt-dependent 
hydrocephalus15,68,75,110,335).
Recommendations
1. CSF drainage, such as EVD and lumbar drainage, is rec-
ommended to treat acute symptomatic hydrocephalus (LOE 
III; GOR B).
2. EVD is recommended for acute hydrocephalus accompa-
nying IVH in the third or fourth ventricles (LOE III; GOR B), 
and lumbar drainage can be considered in cases involving no 
IVH in the third or fourth ventricles and with no possibility 
of supratentorial herniation (LOE IV; GOR C).
3. Permanent diversion of the cerebrospinal fluid is recom-
mended to treat chronic hydrocephalus after aSAHs (LOE III; 
GOR B).
MANAGEMENT OF SEIZURE AND OTHER MEDI-
CAL COMPLICATIONS
Seizure
The incidence of seizure after aSAH is reported to be as high 
as 20%1-9,274), and seizure is known to be an independent risk 
factor for a poor clinical outcome.
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Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. The use of prophylactic anticonvulsants may be considered 
in the immediate posthemorrhagic period (class IIb; LOE B).
2. The routine long-term use of anticonvulsants is not rec-
ommended but may be considered for patients with known risk 
factors for delayed seizure disorder, such as prior seizure, intra-
cerebral hematoma, intractable hypertension, infarction, or an-
eurysm at the middle cerebral artery (class IIb; LOE B).
ESO (2013)312)
1. Antiepileptic treatment should be administered in patients 
with clinically apparent seizure (GCP).
2. There is no evidence that supports the prophylactic use of 
antiepileptic drugs (LOE IV; level C).
JSSC (2008)57)
1. Convulsions induce rebleeding and may worsen the out-
come. Nevertheless, the effect of anticonvulsants administered 
during the initial treatment remains undetermined, although 
convulsion is common immediately after the onset of initial 
bleeding (GOR C).
Evidence
The high incidence of seizures (up to 20%) may be due to the 
inclusion of seizures or seizure-like phenomena that occur at 
the time of aneurysmal rupture or when related complications, 
such as rebleeding, develop17,55,116,133,239). A retrospective cohort 
study reported that approximately 17.9% of patients have pre-
hospital seizures, 7.4% have questionable prehospital seizures, 
and 4.1% have in-hospital seizures271). In approximately 7.8% of 
cases, seizures occur at the time of aSAH onset, while in ap-
proximately 4.1% of cases, after the occurrence of seizures is de-
layed after aSAH45). The incidence of immediate postoperative 
seizures is approximately 2.3%, while the incidence of delayed 
seizures is approximately 5.5%265). In-hospital seizures develop 
an average of 14.5±13.7 days after the onset of aSAHs271). Ac-
cording to the 14-year follow-up of patients enrolled in the 
ISAT, the incidence of seizures was higher in patients who un-
derwent surgical clipping (13.6%) than in patients who under-
went coiling (8.3%) (p=0.014)116). In a Korean study, the inci-
dence of a seizure at the onset of an aSAH was 3.9%, while the 
incidence of a seizure after treatment was 8.7%52,162). 
Anticonvulsants such as phenytoin and levetiracetam are 
conventionally used in patients with aSAHs17,53,225,231,271,280). How-
ever, the duration of anticonvulsant use was found to have no 
association with the recurrence of seizures. The incidence of 
post-discharge seizures is approximately 14%271). For patients 
with aSAHs, a short-term use of anticonvulsants may be more 
beneficial. In a retrospective study, 453 patients with aSAHs were 
divided into two groups-phenytoin was prescribed throughout 
the hospital stay (average 14 days) in one group and for three 
days in the other group. The results indicated that there were 
no significant differences between the two groups regarding 
the incidence of seizures during the hospital stay (1.3% and 
1.9% for 14 days and 3 days, respectively, p=0.6) and during the 
follow-up (5.7% and 4.6% for 14 days and 3 days, respectively, 
p=0.6)53). Another retrospective study compared 442 patients 
with aSAHs by classifying them into the long-term phenytoin 
group (13.7 days) and short-term levetiracetam group (3.6 days); 
the incidence of seizures during the hospital stay was signifi-
cantly higher in the levetiracetam group (8.3%) than in the phe-
nytoin group (3.4%) (p=0.06). However, a smaller number of 
patients in the levetiracetam group showed clinically poor out-
comes (16%) compared to the phenytoin group (24%) (p=0.06)225). 
In a 2.4-year average follow-up of low-risk patients (patients 
who did not present with seizures, cerebral infarction, ICH, 
postoperative hematoma, or accompanying cerebral arteriove-
nous malformation) who used anticonvulsants for an average 
of 5.3 days, the overall incidence of seizures was low (5.4%)17). 
Based on these findings, the short-term use of anticonvulsants 
is considered to have adequate prophylactic effects in patients 
presenting seizures281).
Anticonvulsants have been used to prevent postoperative sei-
zures in patients with aSAHs; however, there are currently no 
clear guidelines for the appropriate timing and efficacy of pro-
phylactic use of anticonvulsants265). Furthermore, there is a pau-
city of randomized controlled trials that support the safety and 
efficacy of the use of prophylactic anticonvulsants. Some clin-
ical trials have reported that prophylactic anticonvulsants ex-
acerbate the clinical outcomes of patients with aSAHs163,231,280). 
In addition, it has been reported that seizures still developed 
after the administration of prophylactic anticonvulsants271). In 
a systematic review, there were no differences in the initial in-
cidence of seizures between a group of patients who used anti-
convulsants (3.0%) and those who did not (2.2%) (p>0.99). 
Furthermore, there was no difference in the early incidence of 
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seizures between the group of patients who underwent clipping 
(2.4%) and those who underwent coiling (1.4%) (p=0.16)265). 
The incidence of delayed seizures also did not differ between 
the anticonvulsant group (5.9%) and the non-anticonvulsant 
group (6.3%) (p>0.99)265). Important risk factors of seizures in 
patients with aSAHs include a poor Hunt-Hess grade (4 and 
5), ICH, and lobectomy162). The risk factors for postoperative 
seizures include aneurysms located in the middle cerebral ar-
tery, symptoms of delayed ischemia, cerebral infarction, hy-
pertension, and ICH52). The incidence of seizures is not high 
in patients with aSAHs, and the development of seizures is as-
sociated with the treatment method for aneurysm obliteration 
(clipping or coiling), volume of aSAHs, location of aneurysms, 
presence of subdural hemorrhage, and the occurrence of cere-
bral infarction55,133,239).
Recommendations
1. Anticonvulsants should be used to treat seizures for pa-
tients with aSAHs (GCP).
2. The use of prophylactic anticonvulsants is generally not 
recommended (LOE III; GOR B). However, the use of prophy-
lactic anticonvulsants can be recommended for patients with 
a high risk of seizures, such as those with delayed seizures, a 
Hunt-Hess grade of 4 or 5, ICH, cerebral infarction, and an 
aneurysm located in the middle cerebral artery as well as those 
who underwent surgical clipping (LOE III; GOR B).
Hyponatremia
Hyponatremia is the most common electrolyte imbalance to 
occur in patients with aSAHs. Failure of timely diagnosis and 
treatment increases subsequent morbidity and mortality.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. The use of fludrocortisone acetate and hypertonic saline 
solution is reasonable for preventing and correcting hyponatre-
mia (class IIa; LOE B).
ESO (2013)312)
1. There is no proof that steroids are effective in patients with 
aSAH (LOE IV; level C).
Evidence
Hyponatremia may be considered an independent risk fac-
tor for poor clinical outcomes in patients with aSAHs119,290). 
Hyponatremia exacerbates cerebral edema, elevates intracra-
nial pressure, and increases seizures and neurological dam-
age224). Because patients with aSAHs require hypertonic fluid 
therapy to control intracranial pressure, their vulnerability to 
hypernatremia is sometimes elevated. A cohort study of 580 
patients with aSAHs reported that there were worse outcomes 
from hypernatremia than from hyponatremia345).
In a randomized controlled study, the use of f ludrocorti-
sone reduced the incidence of hyponatremia in patients with 
aSAHs117). In another randomized controlled study, hydrocor-
tisone was found to more effectively control sodium and plas-
ma concentrations compared to the control group; however, 
there were no differences in the clinical outcomes between the 
two groups157). In general, patients with aSAHs and severe na-
triuresis must take in plenty of water and sodium to increase 
the intravascular volume, which is in turn associated with the 
development of hyponatremia. The use of f ludrocortisone to 
inhibit natriuresis may reduce the need for supplementary so-
dium and water, which may simultaneously prevent hyponatre-
mia223). In a randomized controlled trial, the treatment group 
was administered 1200 mg of hydrocortisone daily, and the 
control group was not administered hydrocortisone. The re-
sults indicated that sodium levels were not reduced below 135 
mmol/L in any of the patients in the treatment group; howev-
er, 43% of the patients in the control group developed hypo-
natremia223). Hence, f ludrocortisone or hydrocortisone may 
contribute to lowering the incidence of hyponatremia268). How-
ever, three large-scale randomized trials with 256 pooled pa-
tients did not elucidate the effects of steroids on clinical out-
comes87).
Recommendations
1. Timely diagnosis and aggressive treatment of hyponatre-
mia are recommended, regardless of the etiology, such as cere-
bral salt wasting syndrome, inappropriate antidiuretic hor-
mone secretion syndrome, excessive fluid therapy and diuretic 
therapy (LOE III; GOR B).
2. An aggressive treatment of hypernatremia is also recom-
mended (LOE III; GOR B).
3. The use of f ludrocortisone or hydrocortisone is recom-
mended to prevent and treat hyponatremia (LOE IIa; GOR B).
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Anemia
Anemia is common in patients with aSAHs, and more than 
47% of patients who develop anemia eventually require blood 
transfusions279,103). Maintaining an adequate hemoglobin level 
may be important for the prevention of DCI; however, sup-
porting evidence is lacking.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. The use of packed red blood cell transfusion to treat ane-
mia might be reasonable in patients with aSAH who are at risk 
of cerebral ischemia. The optimal hemoglobin goal is still to be 
determined (class IIb; LOE B).
Evidence
Anemia can exacerbate DCI by compromising oxygen deliv-
ery to the brain, ultimately exacerbating treatment outcomes. It 
has been suggested that blood transfusions could enhance brain 
oxygen delivery, and some studies reported that blood transfu-
sion improved treatment outcomes and reduced mortali-
ty70,228,230). On the other hand, there have also been reports that 
there is a heightened risk of complications, such as infection, 
thrombosis and cerebral infarction, due to blood transfusions, 
thereby exacerbating negative treatment outcomes and increas-
ing the incidence of vasospasm173,304). According to the only pro-
spective randomized trial of patients with aSAHs who are at 
high risk for vasospasm234), patients whose hemoglobin levels 
were maintained above 11.5 g/dL had a lower prevalence of 
complications than did patients whose hemoglobin levels were 
maintained above 10 g/dL. There were no significant differences 
between the two groups regarding the incidence of cerebral in-
farction and neurological outcomes; however, the high hemo-
globin group tended to have better outcomes234). Although there 
is no report specifying the appropriate hemoglobin level, most 
reports support that maintaining hemoglobin above 11 g/dL is 
desirable228,279,311). There is no consistent evidence as to whether 
the age of transfused red blood cells affects treatment out-
comes173,233). A study suggested that erythropoietin minimizes 
anemia and improves treatment outcomes328); however, it re-
mains unclear whether these are the direct brain-protective ef-
fects of erythropoietin per se or secondary results from in-
creased hemoglobin and reduced transfusion complications.
Recommendations
1. Maintaining a minimum blood hemoglobin value of 11 g/dL 
is recommended for patients with aSAHs and at high risk of va-
sospasm (LOE IIa; GOR B).
Cardiopulmonary complications
It is well known that the neurological outcomes of aSAH are 
exacerbated in proportion to the severity of problems in extra-
cerebral organs112). Mortality from medical complications rang-
es from 0.9% to 2.6%104,296). Medical complications include car-
diovascular, renal, liver, respiratory, and hematologic diseases, 
with cardiopulmonary complications developing at the high-
est incidence112,306). Thus, resolving cardiopulmonary compli-
cations could be critical for improving the prognosis for pa-
tients with aSAH.
Recommendations from foreign guidelines
None
Evidence
Cardiopulmonary complications in patients with aSAHs in-
clude myocardial injury, electrocardiographic abnormalities, 
arrhythmia, myocardial dysfunction, and cardiomyopathy, all 
of which occur at a high incidence and are associated with 
poor outcomes of aSAHs97,235,306,331). According to a prospective 
study294), maintaining a high heart rate increases cardiac com-
plications and induces poor clinical outcomes. The evidence 
supporting treatment methods to improve prognosis is scarce; 
however, some retrospective studies have reported that increas-
ing cardiac output using drugs such as dobutamine or milrinone 
was helpful in maintaining normal cardiovascular functions43). 
There was a prospective study that examined a treatment meth-
od; however, the method is now obsolete235). 
The prevalence of respiratory complications after aSAHs 
ranges from 20–30%43,92,95,111,306). Typical respiratory complica-
tions include pneumonia, neurogenic pulmonary edema, 
acute respiratory distress syndrome, and pulmonary embo-
lism (PE)43,92,95). Respiratory complications have been reported 
to worsen the prognosis in patients with aSAHs95,111,150). A ret-
rospective study has reported that the severity of lung damage 
is directly proportional to prognosis111), while other reports 
have suggested that the presence of respiratory complications 
worsen the prognosis regardless of the severity of the initial 
aSAHs187,188). The standard treatment for respiratory diseases is 
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followed. According to a prospective study, maintaining a nor-
mal global end-diastolic volume overall reduces the incidence 
of DCI and pulmonary edema in patients with aSAHs316).
Recommendations
1. Aggressive treatment is recommended for cardiopulmo-
nary complications that develop after aSAHs, as cardiopulmo-
nary complications can exacerbate patients’ prognoses (LOE 
III; GOR B).
Deep vein thrombosis (DVT) and pulmonary 
embolism
DVT and PE are relatively common complications in pa-
tients with aSAHs. However, focusing on the treatment of the 
aSAH itself may delay the diagnosis and subsequent treatment 
of these serious complications. As an aSAH is a hemorrhagic 
disorder, it is difficult to begin prophylactic anticoagulation 
therapy for DVT and PE. Nevertheless, these complications 
must still be noted and treated, as they are some of the key com-
plications that affect the outcomes of patients with aSAHs.
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. Heparin-induced thrombocytopenia and deep venous 
thrombosis is relatively frequent complication after aSAH. 
Early identification and targeted treatment are recommended, 
but further research is needed to identify the ideal screening 
paradigms (class I; LOE B).
ESO (2013)312)
1. Patients with SAH may be given thromboprophylaxis with 
pneumatic devices and/or compression stockings before occlu-
sion of the aneurysm (LOE II; level B).
2. In case deep vein thrombosis prevention is indicated, low-
molecular-weight heparin should be applied not earlier than 
12 hours after surgical occlusion of the aneurysm and imme-
diately after coiling (LOE II; level B).
Evidence
DVT and PE have a grave impact on the prognosis of patients 
with aSAHs345). DVT is quite common in patients with aSAHs, 
and limiting patient movement, such as with restraints, increases 
the incidence of DVT204,267). A retrospective study based on a US 
inpatient database reported the incidences of DVT and PE in 
patients with aSAHs to be 3.5% and 1.2%, respectively177), and 
the incidence of asymptomatic DVT was as high as 24%267).
The most popular prophylaxis against DVT and PE are pneu-
matic compression and anticoagulation therapy. A study re-
ported that pneumatic compression lowers the incidence of 
DVT29); however, a Cochrane meta-analysis concluded that 
compression stockings are ineffective in stroke patients, while 
intermittent pneumatic compression tends to lower, although 
not significantly, the incidence of DVT226). Although the sub-
jects were not patients with aSAHs, a prospective study exam-
ined a similar group of patients with ICH; reports showed that 
DVT was significantly less prevalent in patients who wore com-
pression stockings and simultaneously underwent intermit-
tent pneumatic compression than in those who only wore com-
pression stockings181).
Another popular treatment is anticoagulation therapy using 
heparin or other anticoagulants similar to low-molecular-weight 
heparin. According to a meta-analysis in patients with acute 
cerebral infarction152), a high dose of heparin decreases the in-
cidence of PE but increases the risk for ICH, while a low dose 
of heparin has prophylactic effects against PE and decreases 
the incidence of ICH. Low-molecular-weight heparin has been 
verified to reduce the incidences of DVT and PE while not in-
creasing the incidence of ICH. Although studies have rarely 
examined patients with aSAHs, a randomized trial of patients 
with aSAHs reported that there were no significant differences 
in the incidence of DVT and PE between patients who were 
administered enoxaparin (40 mg/d) and those who were not303). 
Additional studies are needed to verify the prophylactic effects 
of different types and doses of heparin.
Recommendations
1. DVT and PE are relatively common complications and can 
have adverse effects on the patient’s prognosis; therefore, pro-
phylactic treatment is recommended (LOE III; GOR B).
2. Compression stockings and intermittent pneumatic com-
pression are considered as prophylaxis against DVT and PE 
(LOE IV; GOR C).
EARLY REHABILITATION
The general rehabilitation principles for patients with stroke 
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are recommended for determining the timing of rehabilitation 
for patients with aSAH282). It is generally recommended that re-
habilitation be initiated when a patient is medically and neu-
rologically stable to prevent complications, such as deep vein 
thrombosis, decubitus ulcer, articular contracture, constipa-
tion and pneumonia, and to facilitate functional recovery261). 
The same principles apply to patients with acute aSAH; how-
ever, for neurologically stable patients, acute medical attention 
is still essential for those who have not undergone surgical or 
interventional treatment in the early stage of an acute aSAH198). 
The standardized rehabilitation assessment principles ap-
plied to stroke patients are also recommended for patients with 
aSAHs282). A comprehensive assessment is critical for the deliv-
ery of an appropriate treatment, for quality control, and for the 
assessment of research findings81). In the initial inpatient reha-
bilitation assessment, the patient’s post-stroke physical, cogni-
tive, and verbal sequelae should be diagnosed, and the patient’s 
needs at discharge should be verified261).
Adhering to the principles applied for patients with general 
stroke is also recommended when determining the intensity of 
rehabilitative therapy for patients with aSAH282). Setting an ap-
propriate intensity for rehabilitation therapy is an important 
factor for promoting functional recovery. However, there are 
limited clinical trial data pertaining to the dose-effect relation-
ship of the intensity of rehabilitation therapy, as it is difficult to 
define treatment intensity, structure a rehabilitation program, 
implement blinded procedures, and control the diversity of pa-
tient groups and assessment results178).
Recommendations from foreign guidelines
AHA/ASA (2012)59)
1. After discharge, it is reasonable to refer patients with aneu-
rysmal subarachnoid hemorrhage for a comprehensive evalua-
tion, including cognitive, behavioral, and psychosocial assess-
ments (class IIa; LOE B).
JSSC (2008)57)
1. The difference of outcome at 1 year is reported to be insig-
nificant between the intensive rehabilitation group and the 
control group (GOR B).
2. A shorter hospital stay, better outcome, and higher dis-
charge to home rate is more likely with intensive rehabilitation 
in a stroke unit, rather than an ordinary ward (GOR B).
3. Rehabilitation with emphasis on functional recovery of 
the lower extremity is reported to improve not only ambulato-
ry capability of the patient, but also fine movement of the up-
per extremity and activities of daily living (GOR B).
4. Early treatment of depression after stroke is suggested to 
enhance the effectiveness of rehabilitation (GOR B).
5. The contents and duration of the rehabilitation program, 
rather than the time of initialization, are important (GOR B).
6. Rehabilitation of cognitive functions may improve the 
consciousness level and duration of attention but not the activ-
ities of daily living (GOR B).
Evidence
The effectiveness of early rehabilitation therapy for patients 
with stroke has been elucidated in numerous randomized con-
trolled trials, meta-analyses, and systematic reviews. In a meta-
analysis of 36 randomized controlled trials, Ottenbacher and 
Jannell reported a positive correlation between early rehabilita-
tion therapy and functional recovery in patients with stroke243); 
moreover, there is a stronger association between such func-
tional recovery and the timing of rehabilitation therapy than 
with the duration of rehabilitation therapy. Cifu and Stewart 
published a systematic review of 79 randomized controlled tri-
als that compared post-stroke and post-rehabilitation func-
tional recovery; Cifu and Stewart suggested that the earlier the 
rehabilitation therapy is initiated, the better the functional re-
covery in stroke patients at discharge and during follow-up54). 
The specific timing for initiating rehabilitation therapy should 
be determined based on the stroke severity and the patient’s 
neurological state; however, Hayes and Carroll121) reported 
that beginning rehabilitation therapy within 72 hours post-
stroke produced good outcomes in terms of gait and length of 
hospital stay. They defined early rehabilitation therapy as that 
performed within 24–48 hours of stroke onset121). Olkowski et 
al.241) examined patients with aSAHs who underwent adequate 
surgical or interventional treatment for an aneurysm and re-
ported that applying the same early rehabilitation therapy as 
for patients with stroke to those with SAH was uneventful and 
safe. In addition, Shimamura et al.301) reported that there are 
better functional outcomes if early rehabilitation therapy is 
initiated in patients with SAHs who have had adequate surgi-
cal or interventional treatment for the aneurysm. Approxi-
mately 30% of patients with aSAHs who have not undergone 
treatment for the aneurysm develop rebleeding within one 
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month of onset, and the case fatality rate is approximately 50% 
once rebleeding occurs59,193). Therefore, patients who have not 
had surgical or interventional treatment during the initial 
acute aSAH deserve medical attention for approximately four 
weeks198). In 2013, Ma et al.198) reported that they were unable to 
conduct a meta-analysis of the timing of rehabilitation therapy 
for patients with aSAHs due to the absence of suitable ran-
domized controlled trials on this topic; the lack of data hin-
dered them from drawing conclusions on the safety and effec-
tiveness of early rehabilitation therapy for patients who have 
not had treatment for the aneurysm. In essence, initiating re-
habilitation therapy within 48–72 hours of onset is desirable 
for patients with aSAHs, and clinicians should take note of 
whether the aneurysm was surgically treated, of the risk of the 
aSAH rebleeding, and of the patient’s neurological state when 
initiating rehabilitation therapy.
With regard to the rehabilitation assessment of patients with 
stroke, the Agency for Health Care Policy and Research recom-
mended the use of reliable standardized tools for assessing the 
patient’s neurological state, severity of deficit, functional inde-
pendence, family support, quality of life, and progress over 
time357). A rehabilitation assessment should include an assess-
ment of basic daily living activities (e.g., dressing, washing one’
s face, eating, mobility, and communication) and daily activi-
ties using tools (e.g., cooking, home management, financial 
activities, shopping, and social activities), medical information, 
neurological examination, standardized disability assessment, 
and psychiatric screening tests357). Regarding the timing of the 
rehabilitation assessment, Asberg and Nydevik11) suggested an 
appropriate time frame of 5–7 days following stroke onset. 
However, recent recommendations suggest that assessments 
be performed as early as medical and neurological states per-
mit, and a British guideline recommends that standardized 
assessments be performed within 24 hours of onset282). The 
current recommendation is that trained experts with abun-
dant experience in stroke rehabilitation should perform the 
standardized rehabilitation assessments357).
Although there is a paucity of studies and guidelines per-
taining to the methods of standardized rehabilitation assess-
ment for patients with aSAH, applying the assessment principles 
for patients with general stroke is speculated to be appropriate. 
The effectiveness of rehabilitation therapy in improving the 
functional capacity of patients with stroke for gait and daily 
routines has been well documented, and studies have suggested 
that higher rehabilitation therapy intensity promotes recovery 
of a wider range of functions179,180,184). In a 2004 meta-analysis of 
20 studies with 2686 pooled patients with stroke, increasing 
the intensity of rehabilitation therapy was associated with in-
creased improvements in daily living activities, and perform-
ing at least 16 hours of weekly rehabilitation therapy within six 
months of onset was associated with better recoveries in gait 
and daily living activities337). In a study to survey the improve-
ments in upper limb function associated with rehabilitation 
therapy intensity, reports showed that upper limb function 
significantly improved in the higher intensity treatment group, 
wherein patients underwent additional upper rehabilitation 
therapy313); this finding implies that improvements in upper 
limb function are also associated with the intensity of rehabil-
itation therapy. As shown here, the literature suggests that in-
creasing the rehabilitation therapy intensity by lengthening 
the rehabilitation time promotes better functional recovery in 
patients with stroke; however, it must be noted that recovery 
may be multifactorial, where factors such as the timing of treat-
ment, the severity of brain injury, the degree of medical stabil-
ity, cognitive function, and patient compliance may play a role. 
In particular, the intensity of rehabilitation therapy should be 
determined with meticulous care for patients who have not 
had surgical or interventional treatment for an aneurysm in 
the early phase of onset, as these patients are at a heightened risk 
for rebleeding59,193,198).
Recommendations
1. For patients with acute aSAHs, rehabilitation therapy is 
recommended to be performed as soon as the patients are med-
ically and neurologically stable (LOE III; GOR B).
2. For all patients admitted with acute aSAHs, a specialist is 
considered to perform early rehabilitation assessments as soon 
as possible (LOE IV; GOR C).
3. Standardized and validated assessment instruments are 
considered to be used by experts to screen all patients for de-
pression, dysphagia, and motor, sensory, cognitive and com-
munication impairments (LOE IV; GOR C).
4. An expert from an organized rehabilitation team is con-
sidered to perform standardized assessments of those patients 
identified as having depression, dysphagia, motor or sensory 
dysfunction, and impairments in cognition and communica-
tion at the initial assessment (LOE IV; GOR C).
5. Standardized, validated assessment instruments are con-
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sidered to be used to assess patients’ impairments, functional 
status and participation in community and social activities in 
relation to the stroke (LOE IV; GOR C).
6. The results of standardized assessments are considered to 
be used to predict the prognosis and determine the appropri-
ate level and method of treatment (LOE IV; GOR C).
7. To assist aSAH patients in achieving functional recovery, 
sufficient rehabilitation is considered to be delivered within an 
applicable range of time, in consideration of whether a patient 
has had surgical or interventional treatment for the aneurysms 
(LOE IV; GOR C).
8. The maximum possible rehabilitation treatment programs 
are considered to be facilitated within 6 months after the onset 
of aSAHs (LOE IV; GOR C).
CONCLUSION
The first Korean version of CPGs for aSAH has been issued 
with the aid of many physicians from related academic societ-
ies. These CPGs are based on the most recently published for-
eign as well as domestic articles. The authors expect that these 
CPGs will benefit the physicians who advocate for the best pa-
tient outcomes. Moreover, these CPGs represents a significant 
step forward in conquering aSAH.
CONFLICTS OF INTEREST 
The authors have no financial conflicts of interest.
INFORMED CONSENT
This type of study does not require informed consent.
References
   1. Abruzzo T, Moran C, Blackham KA, Eskey CJ, Lev R, Meyers P, et al. : 
Invasive interventional management of post-hemorrhagic cerebral vaso-
spasm in patients with aneurysmal subarachnoid hemorrhage. J Neuro-
interv Surg 4 : 169-177, 2012
   2. Agid R, Andersson T, Almqvist H, Willinsky RA, Lee SK, terBrugge KG, et 
al. : Negative CT angiography findings in patients with spontaneous 
subarachnoid hemorrhage: when is digital subtraction angiography still 
needed? AJNR Am J Neuroradiol 31 : 696-705, 2010
   3. Al-Rawi PG, Tseng MY, Richards HK, Nortje J, Timofeev I, Matta BF, et 
al. : Hypertonic saline in patients with poor-grade subarachnoid hemor-
rhage improves cerebral blood flow, brain tissue oxygen, and pH. Stroke 
41 : 122-128, 2010
   4. Alberti O, Becker R, Benes L, Wallenfang T, Bertalanffy H : Initial hyper-
glycemia as an indicator of severity of the ictus in poor-grade patients 
with spontaneous subarachnoid hemorrhage. Clin Neurol Neurosurg 
102 : 78-83, 2000
   5. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. : Ce-
rebral arterial spasm--a controlled trial of nimodipine in patients with 
subarachnoid hemorrhage. N Engl J Med 308 : 619-624, 1983
   6. Al-Tamimi YZ, Bhargava D, Feltbower RG, Hall G, Goddard AJ, Quinn AC, et 
al. : Lumbar drainage of cerebrospinal fluid after aneurysmal subarach-
noid hemorrhage: a prospective, randomized, controlled trial (LUMAS). 
Stroke 43 : 677-682, 2012
   7. Amin-Hanjani S, Schwartz RB, Sathi S, Stieg PE : Hypertensive encepha-
lopathy as a complication of hyperdynamic therapy for vasospasm: report 
of two cases. Neurosurgery 44 : 1113-1116, 1999
   8. Anderson SW, Todd MM, Hindman BJ, Clarke WR, Torner JC, Tranel D, et 
al. : Effects of intraoperative hypothermia on neuropsychological out-
comes after intracranial aneurysm surgery. Ann Neurol 60 : 518-527, 
2006
   9. Ando T, Sakai N, Yamada H, Iwai T, Nishimura Y, Hirata T, et al. : Analysis 
of reruptured cerebral aneurysms and the prophylactic effects of barbi-
turate therapy on the early stage. Neurol Res 11 : 245-248, 1989
 10. Appelboom G, Strozyk D, Hwang BY, Prowda J, Badjatia N, Helbok R, et 
al. : Bedside use of a dual aortic balloon occlusion for the treatment of 
cerebral vasospasm. Neurocrit Care 13 : 385-388, 2010
 11. Asberg KH, Nydevik I : Early prognosis of stroke outcome by means of katz 
index of activities of daily living. Scand J Rehabil Med 23 : 187-191, 1991
 12. Auer LM, Mokry M : Disturbed cerebrospinal fluid circulation after sub-
arachnoid hemorrhage and acute aneurysm surgery. Neurosurgery 26 : 
804-808; discussion 808-809, 1990
 13. Badjatia N, Topcuoglu MA, Buonanno FS, Smith EE, Nogueira RG, Rordorf 
GA, et al. : Relationship between hyperglycemia and symptomatic vaso-
spasm after subarachnoid hemorrhage. Crit Care Med 33 : 1603-1609; 
quiz 1623, 2005
 14. Bae DH, Kim JM, Won YD, Choi KS, Cheong JH, Yi HJ, et al. : Clinical out-
come of paraclinoid internal carotid artery aneurysms after microsurgical 
neck clipping in comparison with endovascular embolization. J Cerebro-
vasc Endovasc Neurosurg 16 : 225-234, 2014
 15. Bae IS, Yi HJ, Choi KS, Chun HJ : Comparison of incidence and risk fac-
tors for shunt-dependent hydrocephalus in aneurysmal subarachnoid 
hemorrhage patients. J Cerebrovasc Endovasc Neurosurg 16 : 78-
84, 2014
 16. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn 
J, et al. : Antifibrinolytic therapy for aneurysmal subarachnoid haemor-
rhage. Cochrane Database Syst Rev (8) : CD001245, 2013
 17. Baker CJ, Prestigiacomo CJ, Solomon RA : Short-term perioperative an-
Korean CPG for aSAH | Cho WS, et al.
155J Korean Neurosurg Soc 61 (2) : 127-166
ticonvulsant prophylaxis for the surgical treatment of low-risk patients 
with intracranial aneurysms. Neurosurgery 37 : 863-870; discussion 
870-871, 1995
 18. Bakker NA, Groen RJ, Foumani M, Uyttenboogaart M, Eshghi OS, Metze-
maekers JD, et al. : Repeat digital subtraction angiography after a nega-
tive baseline assessment in nonperimesencephalic subarachnoid hemor-
rhage: a pooled data meta-analysis. J Neurosurg 120 : 99-103, 2014
 19. Barth M, Capelle HH, Weidauer S, Weiss C, Münch E, Thomé C, et al. : 
Effect of nicardipine prolonged-release implants on cerebral vasospasm 
and clinical outcome after severe aneurysmal subarachnoid hemorrhage: 
a prospective, randomized, double-blind phase IIa study. Stroke 38 : 
330-336, 2007
 20. Barth M, Pena P, Seiz M, Thomé C, Muench E, Weidauer S, et al. : Feasibil-
ity of intraventricular nicardipine prolonged release implants in patients 
following aneurysmal subarachnoid haemorrhage. Br J Neurosurg 25 : 
677-683, 2011
 21. Bassi P, Bandera R, Loiero M, Tognoni G, Mangoni A : Warning signs in 
subarachnoid hemorrhage: a cooperative study. Acta Neurol Scand 84 : 
277-281, 1991
 22. Bebawy JF, Zeeni C, Sharma S, Kim ES, DeWood MS, Hemmer LB, et al. : 
Adenosine-induced flow arrest to facilitate intracranial aneurysm clip li-
gation does not worsen neurologic outcome. Anesth Analg 117 : 1205-
1210, 2013
 23. Bellolio MF, Hess EP, Gilani WI, VanDyck TJ, Ostby SA, Schwarz JA, et 
al. : External validation of the Ottawa subarachnoid hemorrhage clinical 
decision rule in patients with acute headache. Am J Emerg Med 33 : 
244-249, 2015
 24. Bendok BR, Gupta DK, Rahme RJ, Eddleman CS, Adel JG, Sherma AK, et 
al. : Adenosine for temporary flow arrest during intracranial aneurysm 
surgery: a single-center retrospective review. Neurosurgery 69 : 815-
820; discussion 820-821, 2011
 25. Benech CA, Perez R, Faccani G, Trompeo AC, Cavallo S, Beninati S, et 
al. : Adenosine-induced cardiac arrest in complex cerebral aneurysms 
surgery: an Italian single-center experience. J Neurosurg Sci 58 : 87-
94, 2014
 26. Bentsen G, Breivik H, Lundar T, Stubhaug A : Hypertonic saline (7.2%) in 
6% hydroxyethyl starch reduces intracranial pressure and improves he-
modynamics in a placebo-controlled study involving stable patients with 
subarachnoid hemorrhage. Crit Care Med 34 : 2912-2917, 2006
 27. Bian L, Liu L, Wang C, Hussain M, Yuan Y, Liu G, et al. : Hyperglycemia 
within day 14 of aneurysmal subarachnoid hemorrhage predicts 1-year 
mortality. Clin Neurol Neurosurg 115 : 956-964, 2013
 28. Bilotta F, Spinelli A, Giovannini F, Doronzio A, Delfini R, Rosa G : The ef-
fect of intensive insulin therapy on infection rate, vasospasm, neurologic 
outcome, and mortality in neurointensive care unit after intracranial 
aneurysm clipping in patients with acute subarachnoid hemorrhage: a 
randomized prospective pilot trial. J Neurosurg Anesthesiol 19 : 156-
160, 2007
 29. Black PM, Baker MF, Snook CP : Experience with external pneumatic calf 
compression in neurology and neurosurgery. Neurosurgery 18 : 440-
444, 1986
 30. Bodily KD, Cloft HJ, Lanzino G, Fiorella DJ, White PM, Kallmes DF : Stent-
assisted coiling in acutely ruptured intracranial aneurysms: a qualitative, 
systematic review of the literature. AJNR Am J Neuroradiol 32 : 1232-
1236, 2011
 31. Bonita R : Cigarette smoking, hypertension and the risk of subarachnoid 
hemorrhage: a population-based case-control study. Stroke 17 : 831-
835, 1986
 32. Bor AS, Koffijberg H, Wermer MJ, Rinkel GJ : Optimal screening strategy 
for familial intracranial aneurysms: a cost-effectiveness analysis. Neurol-
ogy 74 : 1671-1679, 2010
 33. Bor AS, Rinkel GJ, Adami J, Koffijberg H, Ekbom A, Buskens E, et al. : Risk 
of subarachnoid haemorrhage according to number of affected relatives: 
a population based case-control study. Brain 131(Pt 10) : 2662-2665, 
2008
 34. Bor AS, Rinkel GJ, van Norden J, Wermer MJ : Long-term, serial screening 
for intracranial aneurysms in individuals with a family history of aneurys-
mal subarachnoid haemorrhage: a cohort study. Lancet Neurol 13 : 385-
392, 2014
 35. Bor AS, Tiel Groenestege AT, terBrugge KG, Agid R, Velthuis BK, Rinkel 
GJ, et al. : Clinical, radiological, and flow-related risk factors for growth 
of untreated, unruptured intracranial aneurysms. Stroke 46 : 42-48, 
2015
 36. Bota DP, Lefranc F, Vilallobos HR, Brimioulle S, Vincent JL : Ventriculos-
tomy-related infections in critically ill patients: a 6-year experience. J 
Neurosurg 103 : 468-472, 2005
 37. Bracard S, Lebedinsky A, Anxionnat R, Neto JM, Audibert G, Long Y, et 
al. : Endovascular treatment of Hunt and Hess grade IV and V aneurysms. 
AJNR Am J Neuroradiol 23 : 953-957, 2002
 38. Brilstra EH, Rinkel GJ, van der Graaf Y, van Rooij WJ, Algra A : Treatment 
of intracranial aneurysms by embolization with coils: a systematic re-
view. Stroke 30 : 470-476, 1999
 39. Brinjikji W, Kallmes DF, White JB, Lanzino G, Morris JM, Cloft HJ : Inter- 
and intraobserver agreement in CT characterization of nonaneurysmal 
perimesencephalic subarachnoid hemorrhage. AJNR Am J Neuroradiol 
31 : 1103-1105, 2010
 40. Broderick JP, Brown RD Jr, Sauerbeck L, Hornung R, Huston J 3rd, Woo D, 
et al. : Greater rupture risk for familial as compared to sporadic unrup-
tured intracranial aneurysms. Stroke 40 : 1952-1957, 2009
 41. Bromberg JE, Rinkel GJ, Algra A, Greebe P, Beldman T, van Gijn J : Valida-
tion of family history in subarachnoid hemorrhage. Stroke 27 : 630-632, 
1996
 42. Bromberg JE, Rinkel GJ, Algra A, Greebe P, van Duyn CM, Hasan D, et 
al. : Subarachnoid haemorrhage in first and second degree relatives of 
patients with subarachnoid haemorrhage. BMJ 311 : 288-289, 1995
 43. Bruder N, Rabinstein A; Participants in the International Multi-Disciplinary 
Consensus Conference on the Critical Care Management of Subarachnoid 
Hemorrhage : Cardiovascular and pulmonary complications of aneurys-
mal subarachnoid hemorrhage. Neurocrit Care 15 : 257-269, 2011
 44. Burns JD, Huston J 3rd, Layton KF, Piepgras DG, Brown RD Jr : Intracranial 
aneurysm enlargement on serial magnetic resonance angiography: fre-
quency and risk factors. Stroke 40 : 406-411, 2009
J Korean Neurosurg Soc 61 | March 2018
156 https://doi.org/10.3340/jkns.2017.0404.005
 45. Butzkueven H, Evans AH, Pitman A, Leopold C, Jolley DJ, Kaye AH, et al. : 
Onset seizures independently predict poor outcome after subarachnoid 
hemorrhage. Neurology 55 : 1315-1320, 2000
 46. Campi A, Ramzi N, Molyneux AJ, Summers PE, Kerr RS, Sneade M, et al. : 
Retreatment of ruptured cerebral aneurysms in patients randomized by 
coiling or clipping in the International Subarachnoid Aneurysm Trial (ISAT). 
Stroke 38 : 1538-1544, 2007
 47. Canhão P, Pinto AN, Ferro H, Ferro JM : Smoking and aneurysmal sub-
arachnoid haemorrhage: a case-control study. J Cardiovasc Risk 1 : 155-
158, 1994
 48. Carhuapoma JR, Gupta K, Coplin WM, Muddassir SM, Meratee MM : 
Treatment of refractory fever in the neurosciences critical care unit using 
a novel, water-circulating cooling device. A single center pilot experience. 
J Neurosurg Anesthesiol 15 : 313-318, 2003
 49. Carmelli D, Swan GE, Robinette D, Fabsitz R : Genetic influence on smok-
ing--a study of male twins. N Engl J Med 327 : 829-833, 1992
 50. Cha KC, Kim JH, Kang HI, Moon BG, Lee SJ, Kim JS : Aneurysmal rebleed-
ing : factors associated with clinical outcome in the rebleeding patients. 
J Korean Neurosurg Soc 47 : 119-123, 2010
 51. Chang HS, Hongo K, Nakagawa H : Adverse effects of limited hypotensive 
anesthesia on the outcome of patients with subarachnoid hemorrhage. J 
Neurosurg 92 : 971-975, 2000
 52. Chang IB, Cho BM, Shin DI, Shim YB, Park SH, Oh SM : Risk of seizures 
after operative treatment of ruptured cerebral aneurysms. J Korean 
Neurosurg Soc 30 : 705-710, 2001
 53. Chumnanvej S, Dunn IF, Kim DH : Three-day phenytoin prophylaxis is 
adequate after subarachnoid hemorrhage. Neurosurgery 60 : 99-102; 
discussion 102-103, 2007
 54. Cifu DX, Stewart DG : Factors affecting functional outcome after stroke: 
a critical review of rehabilitation interventions. Arch Phys Med Reha-
bil 80(5 Suppl 1) : S35-S39, 1999
 55. Claassen J, Bateman BT, Willey JZ, Inati S, Hirsch LJ, Mayer SA, et al. : 
Generalized convulsive status epilepticus after nontraumatic subarach-
noid hemorrhage: the nationwide inpatient sample. Neurosurgery 61 : 
60-64; discussion 64-65, 2007
 56. Claassen J, Vu A, Kreiter KT, Kowalski RG, Du EY, Ostapkovich N, et al. : 
Effect of acute physiologic derangements on outcome after subarach-
noid hemorrhage. Crit Care Med 32 : 832-838, 2004
 57. Committee for Guidelines for Management of Aneurysmal Subarach-
noid Hemorrhage, Japanese Society on Surgery for Cerebral Stroke : 
Evidence-based guidelines for the management of aneurysmal sub-
arachnoid hemorrhage. English edition. Neurol Med Chir (Tokyo) 52 : 
355-429, 2012
 58. Cong W, Zhongxin Z, Tiangui L, Zhang Y, Min H, Chao Y : Risk factors for 
rebleeding of aneurysmal subarachnoid hemorrhage based on the analy-
sis of on-admission information. Turk Neurosurg 22 : 675-681, 2012
 59. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, 
Higashida RT, et al. : Guidelines for the management of aneurysmal sub-
arachnoid hemorrhage: a guideline for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke 43 : 
1711-1737, 2012
 60. Cortnum S, Sørensen P, Jørgensen J : Determining the sensitivity of com-
puted tomography scanning in early detection of subarachnoid hemor-
rhage. Neurosurgery 66 : 900-902; discussion 903, 2010
 61. Cremers CH, van der Schaaf IC, Wensink E, Greving JP, Rinkel GJ, Velthuis 
BK, et al. : CT perfusion and delayed cerebral ischemia in aneurysmal 
subarachnoid hemorrhage: a systematic review and meta-analysis. J 
Cereb Blood Flow Metab 34 : 200-207, 2014
 62. Dankbaar JW, de Rooij NK, Velthuis BK, Frijns CJ, Rinkel GJ, van der 
Schaaf IC : Diagnosing delayed cerebral ischemia with different CT mo-
dalities in patients with subarachnoid hemorrhage with clinical deterio-
ration. Stroke 40 : 3493-3498, 2009
 63. Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf IC : Effect of different compo-
nents of triple-H therapy on cerebral perfusion in patients with aneurys-
mal subarachnoid haemorrhage: a systematic review. Crit Care 14 : R23, 
2010
 64. de Falco FA : Sentinel headache. Neurol Sci 25 Suppl 3 : S215-S217, 2004
 65. de Gans K, Nieuwkamp DJ, Rinkel GJ, Algra A : Timing of aneurysm sur-
gery in subarachnoid hemorrhage: a systematic review of the literature. 
Neurosurgery 50 : 336-340; discussion 340-342, 2002
 66. de Oliveira JG, Beck J, Setzer M, Gerlach R, Vatter H, Seifert V, et al. : Risk 
of shunt-dependent hydrocephalus after occlusion of ruptured intracranial 
aneurysms by surgical clipping or endovascular coiling: a single-institution 
series and meta-analysis. Neurosurgery 61 : 924-933; discussion 933-
934, 2007
 67. De Sloovere VT : Anesthesia for embolization of cerebral aneurysms. Curr 
Opin Anaesthesiol 27 : 431-436, 2014
 68. Dehdashti AR, Rilliet B, Rufenacht DA, de Tribolet N : Shunt-dependent 
hydrocephalus after rupture of intracranial aneurysms: a prospective 
study of the influence of treatment modality. J Neurosurg 101 : 402-407, 
2004
 69. Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, Scholz JM, Fease 
JL, Anderson RE, et al. : Diagnostic yield of delayed neurovascular imag-
ing in patients with subarachnoid hemorrhage, negative initial CT and 
catheter angiograms, and a negative 7 day repeat catheter angiogram. J 
Neurointerv Surg 6 : 637-642, 2014
 70. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer MN : Red 
blood cell transfusion increases cerebral oxygen delivery in anemic pa-
tients with subarachnoid hemorrhage. Stroke 40 : 3039-3044, 2009
 71. Dhar S, Tremmel M, Mocco J, Kim M, Yamamoto J, Siddiqui AH, et al. : 
Morphology parameters for intracranial aneurysm rupture risk assess-
ment. Neurosurgery 63 : 185-196; discussion 196-197, 2008
 72. Diringer MN; Neurocritical Care Fever Reduction Trial Group : Treatment 
of fever in the neurologic intensive care unit with a catheter-based heat 
exchange system. Crit Care Med 32 : 559-564, 2004
 73. Diringer MN, Reaven NL, Funk SE, Uman GC : Elevated body temperature 
independently contributes to increased length of stay in neurologic in-
tensive care unit patients. Crit Care Med 32 : 1489-1495, 2004
 74. Donmez H, Serifov E, Kahriman G, Mavili E, Durak AC, Menkü A : Com-
parison of 16-row multislice CT angiography with conventional angiogra-
phy for detection and evaluation of intracranial aneurysms. Eur J Radiol 
80 : 455-461, 2011
Korean CPG for aSAH | Cho WS, et al.
157J Korean Neurosurg Soc 61 (2) : 127-166
 75. Dorai Z, Hynan LS, Kopitnik TA, Samson D : Factors related to hydrocepha-
lus after aneurysmal subarachnoid hemorrhage. Neurosurgery 52 : 763-
769; discussion 769-771, 2003
 76. Dorhout Mees SM, Algra A, Vandertop WP, van Kooten F, Kuijsten HA, 
Boiten J, et al. : Magnesium for aneurysmal subarachnoid haemorrhage 
(MASH-2): a randomised placebo-controlled trial. Lancet 380 : 44-49, 
2012
 77. Dorhout Mees SM, Molyneux AJ, Kerr RS, Algra A, Rinkel GJ : Timing of 
aneurysm treatment after subarachnoid hemorrhage: relationship with 
delayed cerebral ischemia and poor outcome. Stroke 43 : 2126-2129, 
2012
 78. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ : Antiplatelet 
therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database 
Syst Rev (4) : CD006184, 2007
 79. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ : Achieved 
serum magnesium concentrations and occurrence of delayed cerebral 
ischaemia and poor outcome in aneurysmal subarachnoid haemorrhage. 
J Neurol Neurosurg Psychiatry 78 : 729-731, 2007
 80. Dorhout Mees SM, van Dijk GW, Algra A, Kempink DR, Rinkel GJ : Glu-
cose levels and outcome after subarachnoid hemorrhage. Neurology 61 : 
1132-1133, 2003
 81. Duncan PW, Horner RD, Reker DM, Samsa GP, Hoenig H, Hamilton B, et 
al. : Adherence to postacute rehabilitation guidelines is associated with 
functional recovery in stroke. Stroke 33 : 167-177, 2002
 82. Dupont SA, Lanzino G, Wijdicks EF, Rabinstein AA : The use of clinical 
and routine imaging data to differentiate between aneurysmal and 
nonaneurysmal subarachnoid hemorrhage prior to angiography. Clinical 
article. J Neurosurg 113 : 790-794, 2010
 83. Edlow JA : Diagnosis of subarachnoid hemorrhage. Neurocrit Care 2 : 
99-109, 2005
 84. Edlow JA : Diagnosing headache in the emergency department: what is 
more important? Being right, or not being wrong? Eur J Neurol 15 : 
1257-1258, 2008
 85. Eskridge JM, Song JK : Endovascular embolization of 150 basilar tip an-
eurysms with guglielmi detachable coils: results of the Food and Drug 
Administration multicenter clinical trial. J Neurosurg 89 : 81-86, 1998
 86. Farrar JK, Gamache FW Jr, Ferguson GG, Barker J, Varkey GP, Drake CG : 
Effects of profound hypotension on cerebral blood flow during surgery 
for intracranial aneurysms. J Neurosurg 55 : 857-864, 1981
 87. Feigin VL, Anderson N, Rinkel GJ, Algra A, van Gijn J, Bennett DA : Cor-
ticosteroids for aneurysmal subarachnoid hemorrhage and primary intra-
cerebral hemorrhage. Cochrane Database of Syst Rev (3) : CD004583, 
2005
 88. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, et al. : 
Risk factors for subarachnoid hemorrhage: an updated systematic review 
of epidemiological studies. Stroke 36 : 2773-2780, 2005
 89. Fernandez A, Schmidt JM, Claassen J, Pavlicova M, Huddleston D, Kreiter 
KT, et al. : Fever after subarachnoid hemorrhage: risk factors and impact 
on outcome. Neurology 68 : 1013-1019, 2007
 90. Fiebach JB, Schellinger PD, Geletneky K, Wilde P, Meyer M, Hacke W, 
et al. : MRI in acute subarachnoid haemorrhage; findings with a stan-
dardised stroke protocol. Neuroradiology 46 : 44-48, 2004
 91. Fisher CM, Kistler JP, Davis JM : Relation of cerebral vasospasm to sub-
arachnoid hemorrhage visualized by computerized tomographic scan-
ning. Neurosurgery 6 : 1-9, 1980
 92. Fontes RB, Aguiar PH, Zanetti MV, Andrade F, Mandel M, Teixeira MJ : 
Acute neurogenic pulmonary edema: case reports and literature review. 
J Neurosurg Anesthesiol 15 : 144-150, 2003
 93. Foreman PM, Chua M, Harrigan MR, Fisher WS 3rd, Tubbs RS, Shoja MM, 
et al. : Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage 
increases the risk for deep venous thrombosis: a case-control study. Clin 
Neurol Neurosurg 139 : 66-69, 2015
 94. Foroohar M, Macdonald RL, Roth S, Stoodley M, Weir B : Intraoperative 
variables and early outcome after aneurysm surgery. Surg Neurol 54 : 
304-315, 2000
 95. Friedman JA, Pichelmann MA, Piepgras DG, Mclver JI, Toussaint LG 3rd, 
McClelland RL, et al. : Pulmonary complications of aneurysmal subarach-
noid hemorrhage. Neurosurgery 52 : 1025-1031; discussion 1031-1032, 
2003
 96. Frontera JA, Fernandez A, Claassen J, Schmidt M, Schumacher HC, 
Wartenberg K, et al. : Hyperglycemia after SAH: predictors, associated 
complications, and impact on outcome. Stroke 37 : 199-203, 2006
 97. Frontera JA, Parra A, Shimbo D, Fernandez A, Schmidt JM, Peter P, et al. : 
Cardiac arrhythmias after subarachnoid hemorrhage: risk factors and im-
pact on outcome. Cerebrovasc Dis 26 : 71-78, 2008
 98. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R : Ultra-early 
rebleeding in spontaneous subarachnoid hemorrhage. J Neurosurg 84 : 
35-42, 1996
 99. Gaberel T, Magheru C, Emery E, Derlon JM : Antifibrinolytic therapy in the 
management of aneurismal subarachnoid hemorrhage revisited. A meta-
analysis. Acta Neurochir (Wien) 154 : 1-9; discussion 9, 2012
100. Gathier CS, van den Bergh WM, Slooter AJ; HIMALAIA-Study Group : 
HIMALAIA (Hypertension Induction in the Management of AneurysmaL 
subArachnoid haemorrhage with secondary IschaemiA): a randomized 
single-blind controlled trial of induced hypertension vs. no induced hy-
pertension in the treatment of delayed cerebral ischemia after subarach-
noid hemorrhage. Int J Stroke 9 : 375-380, 2014
101. Germans MR, Coert BA, Vandertop WP, Verbaan D : Time intervals from 
subarachnoid hemorrhage to rebleed. J Neurol 261 : 1425-1431, 2014
102. Giannotta SL, Oppenheimer JH, Levy ML, Zelman V : Management of in-
traoperative rupture of aneurysm without hypotension. Neurosurgery 
28 : 531-535; discussion 535-536, 1991
103. Giller CA, Wills MJ, Giller AM, Samson D : Distribution of hematocrit values 
after aneurysmal subarachnoid hemorrhage. J Neuroimaging 8 : 169-
170, 1998
104. Gilsbach JM, Harders AG : Morbidity and mortality after early aneurysm 
surgery--a prospective study with nimodipine prevention. Acta Neuro-
chir (Wien) 96 : 1-7, 1989
105. Golan E, Vasquez DN, Ferguson ND, Adhikari NK, Scales DC : Prophy-
lactic magnesium for improving neurologic outcome after aneurysmal 
subarachnoid hemorrhage: systematic review and meta-analysis. J Crit 
Care 28 : 173-181, 2013
J Korean Neurosurg Soc 61 | March 2018
158 https://doi.org/10.3340/jkns.2017.0404.005
106. Gollwitzer S, Groemer T, Rampp S, Hagge M, Olmes D, Huttner HB, et 
al. : Early prediction of delayed cerebral ischemia in subarachnoid hem-
orrhage based on quantitative EEG: a prospective study in adults. Clin 
Neurophysiol 126 : 1514-1523, 2015
107. Greebe P, Bromberg JE, Rinkel GJ, Algra A, van Gijn J : Family history of 
subarachnoid haemorrhage: supplemental value of scrutinizing all rela-
tives. J Neurol Neurosurg Psychiatry 62 : 273-275, 1997
108. Groden C, Kremer C, Regelsberger J, Hansen HC, Zeumer H : Comparison 
of operative and endovascular treatment of anterior circulation aneu-
rysms in patients in poor grades. Neuroradiology 43 : 778-783, 2001
109. Gruber A, Killer M, Bavinzski G, Richling B : Clinical and angiographic re-
sults of endosaccular coiling treatment of giant and very large intracranial 
aneurysms: a 7-year, single-center experience. Neurosurgery 45 : 793-
803; discussion 803-804, 1999
110. Gruber A, Reinprecht A, Bavinzski G, Czech T, Richling B : Chronic shunt-
dependent hydrocephalus after early surgical and early endovascular 
treatment of ruptured intracranial aneurysms. Neurosurgery 44 : 503-
509; discussion 509-512, 1999
111. Gruber A, Reinprecht A, Görzer H, Fridrich P, Czech T, Illievich UM, et al. : 
Pulmonary function and radiographic abnormalities related to neurologi-
cal outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 
88 : 28-37, 1998
112. Gruber A, Reinprecht A, Illievich UM, Fitzgerald R, Dietrich W, Czech T, et 
al. : Extracerebral organ dysfunction and neurologic outcome after an-
eurysmal subarachnoid hemorrhage. Crit Care Med 27 : 505-514, 1999
113. Guinn NR, McDonagh DL, Borel CO, Wright DR, Zomorodi AR, Powers 
CJ, et al. : Adenosine-induced transient asystole for intracranial aneu-
rysm surgery: a retrospective review. J Neurosurg Anesthesiol 23 : 35-
40, 2011
114. Guo LM, Zhou HY, Xu JW, Wang Y, Qiu YM, Jiang JY : Risk factors related 
to aneurysmal rebleeding. World Neurosurg 76 : 292-298; discussion 
253-254, 2011
115. Güresir E, Schuss P, Setzer M, Platz J, Seifert V, Vatter H : Posterior com-
municating artery aneurysm-related oculomotor nerve palsy: influence 
of surgical and endovascular treatment on recovery: single-center series 
and systematic review. Neurosurgery 68 : 1527-1533; discussion 1533-
1534, 2011
116. Hart Y, Sneade M, Birks J, Rischmiller J, Kerr R, Molyneux A : Epilepsy after 
subarachnoid hemorrhage: the frequency or seizures after clip occlusion 
or coil embolization of a ruptured cerebral aneurysm: results from the 
International Subarachnoid Aneurysm Trial. J Neurosurg 115 : 1159-
1168, 2011
117. Hasan D, Lindsay KW, Wijdicks EF, Murray GD, Brouwers PJ, Bakker WH, 
et al. : Effect of fludrocortisone acetate in patients with subarachnoid 
hemorrhage. Stroke 20 : 1156-1161, 1989
118. Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J : Management 
problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke 
20 : 747-753, 1989
119. Hasan D, Wijdicks EF, Vermeulen M : Hyponatremia is associated with ce-
rebral ischemia in patients with aneurysmal subarachnoid hemorrhage. 
Ann Neurol 27 : 106-108, 1990
120. Hayakawa M, Murayama Y, Duckwiler GR, Gobin YP, Guglielmi G, Viñuela 
F : Natural history of the neck remnant of a cerebral aneurysm treated with 
the Guglielmi detachable coil system. J Neurosurg 93 : 561-568, 2000
121. Hayes SH, Carroll SR : Early intervention care in the acute stroke patient. 
Arch Phys Med Rehabil 67 : 319-321, 1986
122. Helbok R, Schmidt JM, Kurtz P, Hanafy KA, Fernandez L, Stuart RM, et 
al. : Systemic glucose and brain energy metabolism after subarachnoid 
hemorrhage. Neurocrit Care 12 : 317-323, 2010
123. Hellingman CA, van den Bergh WM, Beijer IS, van Dijk GW, Algra A, van 
Gijn J, et al. : Risk of rebleeding after treatment of acute hydrocephalus 
in patients with aneurysmal subarachnoid hemorrhage. Stroke 38 : 96-
99, 2007
124. Henderson WG, Torner JC, Nibbelink DW : Intracranial aneurysms and 
subarachnoid hemorrhage --- report on a randomized treatment study. 
IV-B. Regulated bed rest --- statistical evaluation. Stroke 8 : 579-589, 
1977
125. Hernesniemi J, Koivisto T : Comments on “The impact of the International 
Subarachnoid Aneurysm Treatment Trial (ISAT) on neurosurgical prac-
tice”. Acta Neurochir (Wien) 146 : 203-208, 2004
126. Heros RC : Acute hydrocephalus after subarachnoid hemorrhage. Stroke 
20 : 715-717, 1989
127. Hijdra A, Vermeulen M, van Gijn J, van Crevel H : Rerupture of intracra-
nial aneurysms: a clinicoanatomic study. J Neurosurg 67 : 29-33, 1987
128. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE : 
Immediate administration of tranexamic acid and reduced incidence of 
early rebleeding after aneurysmal subarachnoid hemorrhage: a prospec-
tive randomized study. J Neurosurg 97 : 771-778, 2002
129. Hindman BJ, Bayman EO, Pfisterer WK, Torner JC, Todd MM; IHAST Inves-
tigators : No association between intraoperative hypothermia or supple-
mental protective drug and neurologic outcomes in patients undergoing 
temporary clipping during cerebral aneurysm surgery: findings from the 
Intraoperative Hypothermia for Aneurysm Surgery Trial. Anesthesiology 
112 : 86-101, 2010
130. Hitchcock ER, Tsementzis SA, Dow AA : Short- and long-term progno-
sis of patients with a subarachnoid haemorrhage in relation to intra-
operative period of hypotension. Acta Neurochir (Wien) 70 : 235-242, 
1984
131. Hoff RG, Van Dijk GW, Mettes S, Verweij BH, Algra A, Rinkel GJ, et al. : 
Hypotension in anaesthetized patients during aneurysm clipping: not as 
bad as expected? Acta Anaesthesiol Scand 52 : 1006-1011, 2008
132. Hoh BL, Carter BS, Budzik RF, Putman CM, Ogilvy CS : Results after surgi-
cal and endovascular treatment of paraclinoid aneurysms by a combined 
neurovascular team. Neurosurgery 48 : 78-89; discussion 89-90, 2001
133. Hoh BL, Nathoo S, Chi YY, Mocco J, Barker FG 2nd : Incidence of seizures 
or epilepsy after clipping or coiling or ruptured and unruptured cerebral 
aneurysms in the nationwide inpatient sample database: 2002-2007. 
Neurosurgery 69 : 644-650; discussion 650, 2011
134. Hoh BL, Sistrom CL, Firment CS, Fautheree GL, Velat GJ, Whiting JH, et 
al. : Bottleneck factor and height-width ratio: association with ruptured 
aneurysms in patients with multiple cerebral aneurysms. Neurosurgery 
61 : 716-722; discussion 722-723, 2007
Korean CPG for aSAH | Cho WS, et al.
159J Korean Neurosurg Soc 61 (2) : 127-166
135. Hunt WE, Hess RM : Surgical risk as related to time of intervention in the 
repair of intracranial aneurysms. J Neurosurg 28 : 14-20, 1968
136. Huttner HB, Nagel S, Tognoni E, Köhrmann M, Jüttler E, Orakcioglu B, et 
al. : Intracerebral hemorrhage with severe ventricular involvement: lum-
bar drainage for communicating hydrocephalus. Stroke 38 : 183-187, 
2007
137. Huttner HB, Schwab S, Bardutzky J : Lumbar drainage for communicating 
hydrocephalus after ICH with ventricular hemorrhage. Neurocrit Care 5 : 
193-196, 2006
138. Ibrahim GM, Macdonald RL : The effects of fluid balance and colloid 
administration on outcomes in patients with aneurysmal subarachnoid 
hemorrhage: a propensity score-matched analysis. Neurocrit Care 19 : 
140-149, 2013
139. Jakobsson KE, Säveland H, Hillman J, Edner G, Zygmunt S, Brandt L, et al. : 
Warning leak and management outcome in aneurysmal subarachnoid 
hemorrhage. J Neurosurg 85 : 995-999, 1996
140. Johnston SC, Dowd CF, Higashida RT, Lawton MT, Duckwiler GR, Gress 
DR, et al. : Predictors of rehemorrhage after treatment of ruptured in-
tracranial aneurysms: the Cerebral Aneurysm Rerupture After Treatment 
(CARAT) study. Stroke 39 : 120-125, 2008
141. Jones M, Leslie K, Mitchell P : Anaesthesia for endovascular treatment of 
cerebral aneurysms. J Clin Neurosci 11 : 468-470, 2004
142. Jost SC, Diringer MN, Zazulia AR, Videen TO, Aiyagari V, Grubb RL, et 
al. : Effect of normal saline bolus on cerebral blood flow in regions with 
low baseline flow in patients with vasospasm following subarachnoid 
hemorrhage. J Neurosurg 103 : 25-30, 2005
143. Jun P, Ko NU, English JD, Dowd CF, Halbach VV, Higashida RT, et al. : 
Endovascular treatment of medically refractory cerebral vasospasm fol-
lowing aneurysmal subarachnoid hemorrhage. AJNR Am J Neurora-
diol 31 : 1911-1916, 2010
144. Juvela S : Risk factors for multiple intracranial aneurysms. Stroke 31 : 
392-397, 2000
145. Juvela S, Hillbom M, Numminen H, Koskinen P : Cigarette smoking and 
alcohol consumption as risk factors for aneurysmal subarachnoid hemor-
rhage. Stroke 24 : 639-646, 1993
146. Juvela S, Porras M, Poussa K : Natural history of unruptured intracranial 
aneurysms: probability of and risk factors for aneurysm rupture. J Neu-
rosurg 93 : 379-387, 2000
147. Juvela S, Poussa K, Lehto H, Porras M : Natural history of unruptured 
intracranial aneurysms: a long-term follow-up study. Stroke 44 : 2414-
2421, 2013
148. Juvela S, Poussa K, Porras M : Factors affecting formation and growth of 
intracranial aneurysms: a long-term follow-up study. Stroke 32 : 485-
491, 2001
149. Juvela S, Siironen J, Kuhmonen J : Hyperglycemia, excess weight, and 
history of hypertension as risk factors for poor outcome and cerebral in-
farction after aneurysmal subarachnoid hemorrhage. J Neurosurg 102 : 
998-1003, 2005
150. Kahn JM, Caldwell EC, Deem S, Newell DW, Heckbert SR, Rubenfeld GD : 
Acute lung injury in patients with subarachnoid hemorrhage: incidence, 
risk factors, and outcome. Crit Care Med 34 : 196-202, 2006
151. Kalra VB, Wu X, Matouk CC, Malhotra A : Use of follow-up imaging in 
isolated perimesencephalic subarachnoid hemorrhage: a meta-analysis. 
Stroke 46 : 401-406, 2015
152. Kamphuisen PW, Agnelli G : What is the optimal pharmacological pro-
phylaxis for the prevention of deep-vein thrombosis and pulmonary embo-
lism in patients with acute ischemic stroke? Thromb Res 119 : 265-274, 
2007
153. Kan P, Jahshan S, Yashar P, Orion D, Webb S, Siddiqui AH, et al. : Feasibil-
ity, safety, and periprocedural complications associated with endovascu-
lar treatment of selected ruptured aneurysms under conscious sedation 
and local anesthesia. Neurosurgery 72 : 216-220; discussion 220, 2013
154. Kassell NF, Torner JC : Aneurysmal rebleeding: a preliminary report from 
the Cooperative Aneurysm study. Neurosurgery 13 : 479-481, 1983
155. Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP : The International 
Cooperative study on the timing of aneurysm surgery. Part 2: surgical 
results. J Neurosurg 73 : 37-47, 1990
156. Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T : Application of nica-
rdipine prolonged-release implants: analysis of 97 consecutive patients 
with acute subarachnoid hemorrhage. Neurosurgery 56 : 895-902; dis-
cussion 895-902, 2005
157. Katayama Y, Haraoka J, Hirabayashi H, Kawamata T, Kawamoto K, Ki-
tahara T, et al. : A randomized controlled trial of hydrocortisone against 
hyponatremia in patients with aneurysmal subarachnoid hemorrhage. 
Stroke 38 : 2373-2375, 2007
158. Kato Y, Sano H, Dong PT, Panji N, Itezawa Y, Hayashi J, et al. : The effect 
of clipping and coiling in acute severe subarachnoid hemorrhage after 
international subarachnoid aneurysmal trial (ISAT) results. Minim Inva-
sive Neurosurg 48 : 224-227, 2005
159. Khan SA, Agrawal A, Hailey CE, Smith TP, Gokhale S, Alexander MJ, et 
al. : Effect of surgical clipping versus endovascular coiling on recovery 
from oculomotor nerve palsy in patients with posterior communicating 
artery aneurysms: a retrospective comparative study and meta-analysis. 
Asian J Neurosurg 8 : 117-124, 2013
160. Khan SA, McDonagh DL, Adogwa O, Gokhale S, Toche UN, Verla T, et 
al. : Perioperative cardiac complications and 30-day mortality in patients 
undergoing intracranial aneurysmal surgery with adenosine-induced flow 
arrest: a retrospective comparative study. Neurosurgery 74 : 267-271; 
discussion 271-272, 2014
161. Kidwell CS, Wintermark M : Imaging of intracranial haemorrhage. Lan-
cet Neurol 7 : 256-267, 2008
162. Kim TY, Huh SK, Lee JW, Lee KC : Risk factors of seizures associated with 
the management of ruptured cerebral aneurysms. Korean J Cerebro-
vasc Surg 8 : 10-14, 2006
163. Kim YJ, Chun MH : The effect of postoperative anticonvulsant prophy-
laxis after aneurysmal subarachnoid hemorrhage. J Korean Acad Re-
habil Med 27 : 840-844, 2003
164. Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD; STASH 
Collaborators : Simvastatin in aneurysmal subarachnoid haemorrhage 
(STASH): a multicentre randomised phase 3 trial. Lancet Neurol 13 : 
666-675, 2014
165. Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, et 
J Korean Neurosurg Soc 61 | March 2018
160 https://doi.org/10.3340/jkns.2017.0404.005
al. : Subarachnoid hemorrhage: a preventable disease with a heritable 
component. Stroke 33 : 1321-1326, 2002
166. Klimo P Jr, Kestle JR, MacDonald JD, Schmidt RH : Marked reduction of 
cerebral vasospasm with lumbar drainage of cerebrospinal fluid after 
subarachnoid hemorrhage. J Neurosurg 100 : 215-224, 2004
167. Klopfenstein JD, Kim LJ, Feiz-Erfan I, Hott JS, Goslar P, Zabramski JM, et 
al. : Comparison of rapid and gradual weaning from external ventricular 
drainage in patients with aneurysmal subarachnoid hemorrhage: a pro-
spective randomized trial. J Neurosurg 100 : 225-229, 2004
168. Koivisto T, Vanninen R, Hurskainen H, Saari T, Hernesniemi J, Vapalahti M : 
Outcomes of early endovascular versus surgical treatment of ruptured cere-
bral aneurysms. A prospective randomized study. Stroke 31 : 2369-2377, 
2000
169. Korja M, Lehto H, Juvela S : Lifelong rupture risk of intracranial aneurysms 
depends on risk factors: a prospective Finnish Cohort study. Stroke 45 : 
1958-1963, 2014
170. Kosnik EJ, Hunt WE : Postoperative hypertension in the management of 
patients with intracranial arterial aneurysms. J Neurosurg 45 : 148-154, 
1976
171. Kowalski RG, Claassen J, Kreiter KT, Bates JE, Ostapkovich ND, Connolly 
ES, et al. : Initial misdiagnosis and outcome after subarachnoid hemor-
rhage. JAMA 291 : 866-869, 2004
172. Kramer AH, Fletcher JJ : Locally-administered intrathecal thrombolytics 
following aneurysmal subarachnoid hemorrhage: a systematic review 
and meta-analysis. Neurocrit Care 14 : 489-499, 2011
173. Kramer AH, Gurka MJ, Nathan B, Dumont AS, Kassell NF, Bleck TP : Com-
plications associated with anemia and blood transfusion in patients with 
aneurysmal subarachnoid hemorrhage. Crit Care Med 36 : 2070-2075, 
2008
174. Kramer AH, Roberts DJ, Holodinsky J, Todd S, Hill MD, Zygun DA, et al. : 
Intraventricular tissue plasminogen activator in subarachnoid hemorrhage 
patients: a prospective, randomized, placebo-controlled pilot trial. Neu-
rocrit Care 21 : 275-284, 2014
175. Kronvall E, Undrén P, Romner B, Säveland H, Cronqvist M, Nilsson OG : Ni-
modipine in aneurysmal subarachnoid hemorrhage: a randomized study 
of intravenous or peroral administration. J Neurosurg 110 : 58-63, 2009
176. Kruyt ND, Roos YW, Dorhout Mees SM, van den Bergh WM, Algra A, 
Rinkel GJ, et al. : High mean fasting glucose levels independently predict 
poor outcome and delayed cerebral ischaemia after aneurysmal sub-
arachnoid haemorrhage. J Neurol Neurosurg Psychiatry 79 : 1382-
1385, 2008
177. Kshettry VR, Rosenbaum BP, Seicean A, Kelly ML, Schiltz NK, Weil RJ : 
Incidence and risk factors associated with in-hospital venous thrombo-
embolism after aneurysmal subarachnoid hemorrhage. J Clin Neurosci 
21 : 282-286, 2014
178. Kwakkel G : Impact of intensity of practice after stroke: issues for con-
sideration. Disabil Rehabil 28 : 823-830, 2006
179. Kwakkel G, van Peppen R, Wagenaar RC, Wood Dauphinee S, Richards 
C, Ashburn A, et al. : Effects of augmented exercise therapy time after 
stroke: a meta-analysis. Stroke 35 : 2529-2539, 2004
180. Kwakkel G, Wagenaar RC, Koelman TW, Lankhorst GJ, Koetsier JC : Ef-
fects of intensity of rehabilitation after stroke. A research synthesis. 
Stroke 28 : 1550-1556, 1997
181. Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniac A, Renault A, et 
al. : Prevention of venous thrombosis in patients with acute intracerebral 
hemorrhage. Neurology 65 : 865-869, 2005
182. Laidlaw JD, Siu KH : Ultra-early surgery for aneurysmal subarachnoid hem-
orrhage: outcomes for a consecutive series of 391 patients not selected 
by grade or age. J Neurosurg 97 : 250-258; discussion 247-249, 2002
183. Lakhani S, Guha A, Nahser HC : Anaesthesia for endovascular manage-
ment of cerebral aneurysms. Eur J Anaesthesiol 23 : 902-913, 2006
184. Langhorne P, Wagenaar R, Partridge C : Physiotherapy after stroke: more 
is better? Physiother Res Int 1 : 75-88, 1996
185. Lanzino G, Kassell NF, Germanson T, Truskowski L, Alves W : Plasma glu-
cose levels and outcome after aneurysmal subarachnoid hemorrhage. J 
Neurosurg 79 : 885-891, 1993
186. Latorre JG, Chou SH, Nogueira RG, Singhal AB, Carter BS, Ogilvy CS, et 
al. : Effective glycemic control with aggressive hyperglycemia manage-
ment is associated with improved outcome in aneurysmal subarachnoid 
hemorrhage. Stroke 40 : 1644-1652, 2009
187. Le Roux PD, Elliott JP, Downey L, Newell DW, Grady MS, Mayberg MR, et 
al. : Improved outcome after rupture of anterior circulation aneurysms: a 
retrospective 10-year review of 224 good-grade patients. J Neurosurg 
83 : 394-402, 1995
188. Le Roux PD, Elliott JP, Newell DW, Grady MS, Winn HR : Predicting out-
come in poor grade patients with subarachnoid hemorrhage: a retro-
spective review of 159 aggressively managed cases. J Neurosurg 85 : 
39-49, 1996
189. Lee SH, Lim JS, Kim N, Yoon BW : Effects of admission glucose level on 
mortality after subarachnoid hemorrhage: a comparison between short-
term and long-term mortality. J Neurol Sci 275 : 18-21, 2008
190. Levati A, Tommasino C, Moretti MP, Paino R, D’Aliberti G, Santoro F, et 
al. : Giant intracranial aneurysms treated with deep hypothermia and 
circulatory arrest. J Neurosurg Anesthesiol 19 : 25-30, 2007
191. Li H, Pan R, Wang H, Rong X, Yin Z, Milgrom DP, et al. : Clipping versus 
coiling for ruptured intracranial aneurysms: a systematic review and meta-
analysis. Stroke 44 : 29-37, 2013
192. Lindsay KW, Teasdale G, Knill-Jones RP, Murray L : Observer variability in 
grading patients with subarachnoid hemorrhage. J Neurosurg 56 : 628-
633, 1982
193. Locksley HB : Natural history of subarachnoid hemorrhage, intracranial 
aneurysms and arteriovenous malformations. J Neurosurg 25 : 321-368, 
1966
194. Longstreth WT Jr, Nelson LM, Koepsell TD, van Belle G : Cigarette smok-
ing, alcohol use, and subarachnoid hemorrhage. Stroke 23 : 1242-1249, 
1992
195. Luo YC, Shen CS, Mao JL, Liang CY, Zhang Q, He ZJ : Ultra-early versus 
delayed coil treatment for ruptured poor-grade aneurysm. Neuroradi-
ology 57 : 205-210, 2015
196. Luostarinen T, Takala RS, Niemi TT, Katila AJ, Niemelä M, Hernesniemi J, 
et al. : Adenosine-induced cardiac arrest during intraoperative cerebral 
aneurysm rupture. World Neurosurg 73 : 79-83; discussion e9, 2010
Korean CPG for aSAH | Cho WS, et al.
161J Korean Neurosurg Soc 61 (2) : 127-166
197. Lusseveld E, Brilstra EH, Nijssen PC, van Rooij WJ, Sluzewski M, Tulleken 
CA, et al. : Endovascular coiling versus neurosurgical clipping in patients 
with a ruptured basilar tip aneurysm. J Neurol Neurosurg Psychiatry 
73 : 591-593, 2002
198. Ma Z, Wang Q, Liu M : Early versus delayed mobilisation for aneurysmal 
subarachnoid haemorrhage. Cochrane Database Syst Rev (5) : CD008346, 
2013
199. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, 
et al. : Clazosentan, an endothelin receptor antagonist, in patients with 
aneurysmal subarachnoid haemorrhage undergoing surgical clipping: 
a randomised, double-blind, placebo-controlled phase 3 trial (CON-
SCIOUS-2). Lancet Neurol 10 : 618-625, 2011
200. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe 
A, et al. : Randomized trial of clazosentan in patients with aneurysmal 
subarachnoid hemorrhage undergoing endovascular coiling. Stroke 43 : 
1463-1469, 2012
201. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Wei-
dauer S, et al. : Clazosentan to overcome neurological ischemia and 
infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): 
randomized, double-blind, placebo-controlled phase 2 dose-finding trial. 
Stroke 39 : 3015-3021, 2008
202. Macdonald RL, Pluta RM, Zhang JH : Cerebral vasospasm after subarach-
noid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3 : 
256-263, 2007
203. Mack WJ, Ducruet AF, Angevine PD, Komotar RJ, Shrebnick DB, Edwards 
NM, et al. : Deep hypothermic circulatory arrest for complex cerebral an-
eurysms: lessons learned. Neurosurgery 60 : 815-827; discussion 815-
827, 2007
204. Mack WJ, Ducruet AF, Hickman ZL, Kalyvas JT, Cleveland JR, Mocco J, et 
al. : Doppler ultrasonography screening of poor-grade subarachnoid 
hemorrhage patients increases the diagnosis of deep venous thrombosis. 
Neurol Res 30 : 889-892, 2008
205. Manninen PH, Chan AS, Papworth D : Conscious sedation for interven-
tional neuroradiology: a comparison of midazolam and propofol infusion. 
Can J Anaesth 44 : 26-30, 1997
206. Maslehaty H, Petridis AK, Barth H, Mehdorn HM : Diagnostic value of 
magnetic resonance imaging in perimesencephalic and nonperimesence-
phalic subarachnoid hemorrhage of unknown origin. J Neurosurg 114 : 
1003-1007, 2011
207. Matsuda M, Watanabe K, Saito A, Matsumura K, Ichikawa M : Circum-
stances, activities, and events precipitating aneurysmal subarachnoid 
hemorrhage. J Stroke Cerebrovasc Dis 16 : 25-29, 2007
208. McCormack RF, Hutson A : Can computed tomography angiography 
of the brain replace lumbar puncture in the evaluation of acute-onset 
headache after a negative noncontrast cranial computed tomography 
scan? Acad Emerg Med 17 : 444-451, 2010
209. McDougall CG, Halbach VV, Dowd CF, Higashida RT, Larsen DW, Hieshi-
ma GB : Endovascular treatment of basilar tip aneurysms using electro-
lytically detachable coils. J Neurosurg 84 : 393-399, 1996
210. McDougall CG, Spetzler RF, Zabramski JM, Partovi S, Hills NK, Nakaji P, 
et al. : The barrow ruptured aneurysm trial. J Neurosurg 116 : 135-144, 
2012
211. McGirt MJ, Woodworth GF, Ali M, Than KD, Tamargo RJ, Clatterbuck RE : 
Persistent perioperative hyperglycemia as an independent predictor of 
poor outcome after aneurysmal subarachnoid hemorrhage. J Neuro-
surg 107 : 1080-1085, 2007
212. McIver JI, Friedman JA, Wijdicks EF, Piepgras DG, Pichelmann MA, Tous-
saint LG 3rd, et al. : Preoperative ventriculostomy and rebleeding after 
aneurysmal subarachnoid hemorrhage. J Neurosurg 97 : 1042-1044, 
2002
213. McKinney AM, Palmer CS, Truwit CL, Karagulle A, Teksam M : Detection 
of aneurysms by 64-section multidetector CT angiography in patients 
acutely suspected of having an intracranial aneurysm and comparison 
with digital subtraction and 3D rotational angiography. AJNR Am J Neu-
roradiol 29 : 594-602, 2008
214. McNeill L, English SW, Borg N, Matta BF, Menon DK : Effects of institu-
tional caseload of subarachnoid hemorrhage on mortality: a secondary 
analysis of administrative data. Stroke 44 : 647-652, 2013
215. Menke J, Larsen J, Kallenberg K : Diagnosing cerebral aneurysms by com-
puted tomographic angiography: meta-analysis. Ann Neurol 69 : 646-
654, 2011
216. Milhorat TH : Acute hydrocephalus after aneurysmal subarachnoid hem-
orrhage. Neurosurgery 20 : 15-20, 1987
217. Mir DI, Gupta A, Dunning A, Puchi L, Robinson CL, Epstein HA, et al. : 
CT perfusion for detection of delayed cerebral ischemia in aneurysmal 
subarachnoid hemorrhage: a systematic review and meta-analysis. AJNR 
Am J Neuroradiol 35 : 866-871, 2014
218. Mitchell P, Kerr R, Mendelow AD, Molyneux A : Could late rebleeding 
overturn the superiority of cranial aneurysm coil embolization over clip 
ligation seen in the international subarachnoid aneurysm trial? J Neu-
rosurg 108 : 437-442, 2008
219. Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et 
al. : International subarachnoid aneurysm trial (ISAT) of neurosurgical 
clipping versus endovascular coiling in 2143 patients with ruptured in-
tracranial aneurysms: a randomised trial. Lancet 360 : 1267-1274, 2002
220. Molyneux AJ, Birks J, Clarke A, Sneade M, Kerr RS : The durability of en-
dovascular coiling versus neurosurgical clipping of ruptured cerebral 
aneurysms: 18 year follow-up of the UK cohort of the international sub-
arachnoid aneurysm trial (ISAT). Lancet 385 : 691-697, 2015
221. Molyneux AJ, Kerr RS, Birks J, Ramzi N, Yarnold J, Sneade M, et al. : Risk 
of recurrent subarachnoid haemorrhage, death, or dependence and 
standardised mortality ratios after clipping or coiling of an intracranial 
aneurysm in the international subarachnoid aneurysm trial (ISAT): long-
term follow-up. Lancet Neurol 8 : 427-433, 2009
222. Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. : In-
ternational subarachnoid aneurysm trial (ISAT) of neurosurgical clipping 
versus endovascular coiling in 2143 patients with ruptured intracranial 
aneurysms: a randomised comparison of effects on survival, dependen-
cy, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 
366 : 809-817, 2005
223. Mori T, Katayama Y, Kawamata T, Hirayama T : Improved efficiency of 
hypervolemic therapy with inhibition of natriuresis by fludrocortisone in 
J Korean Neurosurg Soc 61 | March 2018
162 https://doi.org/10.3340/jkns.2017.0404.005
patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 91 : 
947-952, 1999
224. Mount DB : The brain in hyponatremia: both culprit and victim. Semin 
Nephrol 29 : 196-215, 2009
225. Murphy-Human T, Welch E, Zipfel G, Diringer MN, Dhar R : Comparison 
of short-duration levetiracetam with extended course phenytoin for sei-
zure prophylaxis after subarachnoid hemorrhage. World Neurosurg 75 : 
269-274, 2011
226. Naccarato M, Chiodo Grandi F, Dennis M, Sandercock PA : Physical 
methods for preventing deep vein thrombosis in stroke. Cochrane Da-
tabase Syst Rev (8) : CD001922, 2010
227. Naidech AM, Bendok BR, Bernstein RA, Alberts MJ, Batjer HH, Watts 
CM, et al. : Fever burden and functional recovery after subarachnoid 
hemorrhage. Neurosurgery 63 : 212-217; discussion 217-218, 2008
228. Naidech AM, Drescher J, Ault ML, Shaibani A, Batjer HH, Alberts MJ : 
Higher hemoglobin is associated with less cerebral infarction, poor out-
come, and death after subarachnoid hemorrhage. Neurosurgery 59 : 
775-779; discussion 779-780, 2006
229. Naidech AM, Janjua N, Kreiter KT, Ostapkovich ND, Fitzsimmons BF, 
Parra A, et al. : Predictors and impact of aneurysm rebleeding after sub-
arachnoid hemorrhage. Arch Neurol 62 : 410-416, 2005
230. Naidech AM, Jovanovic B, Wartenberg KE, Parra A, Ostapkovich N, Con-
nolly ES, et al. : Higher hemoglobin is associated with improved outcome 
after subarachnoid hemorrhage. Crit Care Med 35 : 2383-2389, 2007
231. Naidech AM, Kreiter KT, Janjua N, Ostapkovich N, Parra A, Commichau 
C, et al. : Phenytoin exposure is associated with functional and cognitive 
disability after subarachnoid hemorrhage. Stroke 36 : 583-587, 2005
232. Naidech AM, Levasseur K, Liebling S, Garg RK, Shapiro M, Ault ML, et al. : 
Moderate hypoglycemia is associated with vasospasm, cerebral infarc-
tion, and 3-month disability after subarachnoid hemorrhage. Neurocrit 
Care 12 : 181-187, 2010
233. Naidech AM, Liebling SM, Duran IM, Ault ML : Packed red blood cell age 
does not impact adverse events or outcomes after subarachnoid haem-
orrhage. Transfus Med 21 : 130-133, 2011
234. Naidech AM, Shaibani A, Garg RK, Duran IM, Liebling SM, Bassin SL, et 
al. : Prospective, randomized trial of higher goal hemoglobin after sub-
arachnoid hemorrhage. Neurocrit Care 13 : 313-320, 2010
235. Neil-Dwyer G, Walter P, Cruickshank JM, Doshi B, O’Gorman P : Effect of 
propranolol and phentolamine on myocardial necrosis after subarachnoid 
haemorrhage. Br Med J 2 : 990-992, 1978
236. Nguyen HP, Zaroff JG, Bayman EO, Gelb AW, Todd MM, Hindman BJ, 
et al. : Perioperative hypothermia (33 degrees C) does not increase the 
occurrence of cardiovascular events in patients undergoing cerebral 
aneurysm surgery: findings from the Intraoperative Hypothermia for An-
eurysm Surgery Trial. Anesthesiology 113 : 327-342, 2010
237. Ogilvy CS : Neurosurgical clipping versus endovascular coiling of patients 
with ruptured intracranial aneurysms. Stroke 34 : 2540-2542, 2003
238. Ohkuma H, Tsurutani H, Suzuki S : Incidence and significance of early an-
eurysmal rebleeding before neurosurgical or neurological management. 
Stroke 32 : 1176-1180, 2001
239. Olafsson E, Gudmundsson G, Hauser WA : Risk of epilepsy in long-term 
survivors of surgery for aneurysmal subarachnoid hemorrhage: a popu-
lation-based study in Iceland. Epilepsia 41 : 1201-1205, 2000
240. Oliveira-Filho J, Ezzeddine MA, Segal AZ, Buonanno FS, Chang Y, Ogilvy 
CS, et al. : Fever in subarachnoid hemorrhage: relationship to vasospasm 
and outcome. Neurology 56 : 1299-1304, 2001
241. Olkowski BF, Devine MA, Slotnick LE, Veznedaroglu E, Liebman KM, Ar-
caro ML, et al. : Safety and feasibility of an early mobilization program 
for patients with aneurysmal subarachnoid hemorrhage. Phys Ther 93 : 
208-215, 2013
242. Oshiro EM, Walter KA, Piantadosi S, Witham TF, Tamargo RJ : A new 
subarachnoid hemorrhage grading system based on the glasgow coma 
scale: a comparison with the Hunt and Hess and World Federation of 
Neurological Surgeons scales in a clinical series. Neurosurgery 41 : 140-
147; discussion 147-148, 1997
243. Ottenbacher KJ, Jannell S : The results of clinical trials in stroke rehabili-
tation research. Arch Neurol 50 : 37-44, 1993
244. Pan JW, Zhan RY, Wen L, Tong Y, Wan S, Zhou YY : Ultra-early surgery for 
poor-grade intracranial aneurysmal subarachnoid hemorrhage: a prelimi-
nary study. Yonsei Med J 50 : 521-524, 2009
245. Paré L, Delfino R, Leblanc R : The relationship of ventricular drainage to 
aneurysmal rebleeding. J Neurosurg 76 : 422-427, 1992
246. Park J, Woo H, Kang DH, Kim YS, Kim MY, Shin IH, et al. : Formal protocol 
for emergency treatment of ruptured intracranial aneurysms to reduce 
in-hospital rebleeding and improve clinical outcomes. J Neurosurg 122 : 
383-391, 2015
247. Pasternak JJ, McGregor DG, Schroeder DR, Lanier WL, Shi Q, Hindman BJ, 
et al. : Hyperglycemia in patients undergoing cerebral aneurysm surgery: 
its association with long-term gross neurologic and neuropsychological 
function. Mayo Clin Proc 83 : 406-417, 2008
248. Patel K, Guilfoyle MR, Bulters DO, Kirollos RW, Antoun NM, Higgins JN, 
et al. : Recovery of oculomotor nerve palsy secondary to posterior com-
municating artery aneurysms. Br J Neurosurg 28 : 483-487, 2014
249. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Hohl CM, Sutherland J, et al. : 
Clinical decision rules to rule out subarachnoid hemorrhage for acute 
headache. JAMA 310 : 1248-1255, 2013
250. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Lee JS, Eisenhauer M, et al. : 
High risk clinical characteristics for subarachnoid haemorrhage in pa-
tients with acute headache: prospective cohort study. BMJ 341 : c5204, 
2010
251. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, 
et al. : Effect of oral nimodipine on cerebral infarction and outcome after 
subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298 : 
636-642, 1989
252. Pierot L, Cognard C, Anxionnat R, Ricolfi F; CLARITY Investigators : Re-
modeling technique for endovascular treatment of ruptured intracranial 
aneurysms had a higher rate of adequate postoperative occlusion than 
did conventional coil embolization with comparable safety. Radiology 
258 : 546-553, 2011
253. Pierot L, Cognard C, Spelle L, Moret J : Safety and efficacy of balloon remod-
eling technique during endovascular treatment of intracranial aneurysms: 
critical review of the literature. AJNR Am J Neuroradiol 33 : 12-15, 
Korean CPG for aSAH | Cho WS, et al.
163J Korean Neurosurg Soc 61 (2) : 127-166
2012
254. Polmear A : Sentinel headaches in aneurysmal subarachnoid haemor-
rhage: what is the true incidence? A systematic review. Cephalalgia 23 : 
935-941, 2003
255. Powers CJ, Wright DR, McDonagh DL, Borel CO, Zomorodi AR, Britz GW : 
Transient adenosine-induced asystole during the surgical treatment of 
anterior circulation cerebral aneurysms: technical note. Neurosurgery 
67(2 Suppl Operative) : 461-470, 2010
256. Proust F, Gérardin E, Derrey S, Lesvèque S, Ramos S, Langlois O, et al. : 
Interdisciplinary treatment of ruptured cerebral aneurysms in elderly pa-
tients. J Neurosurg 112 : 1200-1207, 2010
257. Qureshi AI, Suri MF, Khan J, Kim SH, Fessler RD, Ringer AJ, et al. : Endo-
vascular treatment of intracranial aneurysms by using guglielmi detach-
able coils in awake patients: safety and feasibility. J Neurosurg 94 : 880-
885, 2001
258. Raaymakers TW : Aneurysms in relatives of patients with subarachnoid 
hemorrhage: frequency and risk factors. MARS Study Group. Magnetic 
Resonance Angiography in Relatives of patients with subarachnoid hem-
orrhage. Neurology 53 : 982-988, 1999
259. Rabinstein AA, Lanzino G, Wijdicks EF : Multidisciplinary management 
and emerging therapeutic strategies in aneurysmal subarachnoid haem-
orrhage. Lancet Neurol 9 : 504-519, 2010
260. Raftopoulos C, Mathurin P, Boscherini D, Billa RF, Van Boven M, Hantson 
P : Prospective analysis of aneurysm treatment in a series of 103 con-
secutive patients when endovascular embolization is considered the first 
option. J Neurosurg 93 : 175-182, 2000
261. Rah UW, Kim YH, Ohn SH, Chun MH, Kim MW, Yoo WK, et al. : Clinical 
practice guideline for stroke rehabilitation in Korea 2012. Brain Neuro-
rehabil 7(Suppl 1) : S1-S75, 2014
262. Rahman M, Smietana J, Hauck E, Hoh B, Hopkins N, Siddiqui A, et al. : 
Size ratio correlates with intracranial aneurysm rupture status: a prospec-
tive study. Stroke 41 : 916-920, 2010
263. Rajshekhar V, Harbaugh RE : Results of routine ventriculostomy with ex-
ternal ventricular drainage for acute hydrocephalus following subarach-
noid haemorrhage. Acta Neurochir (Wien) 115 : 8-14, 1992
264. Ransom ER, Mocco J, Komotar RJ, Sahni D, Chang J, Hahn DK, et al. : 
External ventricular drainage response in poor grade aneurysmal sub-
arachnoid hemorrhage: effect on preoperative grading and prognosis. 
Neurocrit Care 6 : 174-180, 2007
265. Raper DM, Starke RM, Komotar RJ, Allan R, Connolly ES Jr : Seizures after 
aneurysmal subarachnoid hemorrhage: a systematic review of outcomes. 
World Neurosurg 79 : 682-690, 2013
266. Ray WZ, Moran CJ, Derdeyn CP, Diringer MN, Dacey RG Jr, Zipfel GJ : 
Near-complete resolution of angiographic cerebral vasospasm after ex-
treme elevation of mean arterial pressure: case report. Surg Neurol 72 : 
347-353; discussion 353-354, 2009
267. Ray WZ, Strom RG, Blackburn SL, Ashley WW, Sicard GA, Rich KM : 
Incidence of deep venous thrombosis after subarachnoid hemorrhage. J 
Neurosurg 110 : 1010-1014, 2009
268. Raya AK, Diringer MN : Treatment of subarachnoid hemorrhage. Crit 
Care Clin 30 : 719-733, 2014
269. Reddy D, Fallah A, Petropoulos JA, Farrokhyar F, Macdonald RL, Jichici D : 
Prophylactic magnesium sulfate for aneurysmal subarachnoid hemor-
rhage: a systematic review and meta-analysis. Neurocrit Care 21 : 356-
364, 2014
270. Regli L, Dehdashti AR, Uske A, de Tribolet N : Endovascular coiling com-
pared with surgical clipping for the treatment of unruptured middle cerebral 
artery aneurysms: an update. Acta Neurochir Suppl 82 : 41-46, 2002
271. Rhoney DH, Tipps LB, Murry KR, Basham MC, Michael DB, Coplin WM : 
Anticonvulsant prophylaxis and timing of seizures after aneurysmal sub-
arachnoid hemorrhage. Neurology 55 : 258-265, 2000
272. Rinkel GJ, Djibuti M, Algra A, van Gijn J : Prevalence and risk of rupture 
of intracranial aneurysms: a systematic review. Stroke 29 : 251-256, 
1998
273. Rivero Rodríguez D, Scherle Matamoros C, Fernández Cúe L, Miranda 
Hernández JL, Pernas Sánchez Y, Pérez Nellar J : Factors associated with 
poor outcome for aneurysmal subarachnoid haemorrhage in a series of 
334 patients. Neurologia 32 : 15-21, 2017
274. United States Agency for health care policy and research : Acute Pain 
Management: Operative or Medical Procedures and Trauma: 
Clinical Practice Guideline, ed 1. Rockville : United States Agency for 
health care policy and research, 1992, pp1-145
275. Roessler K, Krawagna M, Dörfler A, Buchfelder M, Ganslandt O : Essen-
tials in intraoperative indocyanine green videoangiography assessment 
for intracranial aneurysm surgery: conclusions from 295 consecutively 
clipped aneurysms and review of the literature. Neurosurg Focus 36 : 
E7, 2014
276. Ronkainen A, Hernesniemi J, Ryynänen M : Familial subarachnoid hemor-
rhage in east Finland, 1977-1990. Neurosurgery 33 : 787-796; discussion 
796-797, 1993
277. Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, 
et al. : Risk of harboring an unruptured intracranial aneurysm. Stroke 29 : 
359-362, 1998
278. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J : Antifibrinolytic 
therapy for aneurysmal subarachnoid haemorrhage. Cochrane Data-
base Syst Rev (2) : CD001245, 2003
279. Rosenberg NF, Koht A, Naidech AM : Anemia and transfusion after aneu-
rysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol 25 : 66-
74, 2013
280. Rosengart AJ, Huo JD, Tolentino J, Novakovic RL, Frank JI, Goldenberg 
FD, et al. : Outcome in patients with subarachnoid hemorrhage treated 
with antiepileptic drugs. J Neurosurg 107 : 253-260, 2007
281. Rowe AS, Goodwin H, Brophy GM, Bushwitz J, Castle A, Deen D, et al. : 
Seizure prophylaxis in neurocritical care: a review of evidence-based sup-
port. Pharmacotherapy 34 : 396-409, 2014
282. Royal College of Physicians : National Clinical Guideline for Stroke, 
ed 4. London : Royal College of Physicians of London, 2012, pp79-123
283. Ruigrok YM, Buskens E, Rinkel GJ : Attributable risk of common and rare 
determinants of subarachnoid hemorrhage. Stroke 32 : 1173-1175, 2001
284. Ryttlefors M, Enblad P, Kerr RS, Molyneux AJ : International subarach-
noid aneurysm trial of neurosurgical clipping versus endovascular coiling: 
subgroup analysis of 278 elderly patients. Stroke 39 : 2720-2726, 2008
J Korean Neurosurg Soc 61 | March 2018
164 https://doi.org/10.3340/jkns.2017.0404.005
285. Sakurai J, Ushikoshi S, Terasaka S, Kazumata K, Asaoka K, Ajiki M, et al. : 
The role of endovascular treatment for multiple intracranial aneurysms 
with subarachnoid hemorrhage. No Shinkei Geka 35 : 143-149, 2007
286. Sankai T, Iso H, Shimamoto T, Kitamura A, Naito Y, Sato S, et al. : Prospec-
tive study on alcohol intake and risk of subarachnoid hemorrhage among 
Japanese men and women. Alcohol Clin Exp Res 24 : 386-389, 2000
287. Santillan A, Knopman J, Zink W, Patsalides A, Gobin YP : Transluminal bal-
loon angioplasty for symptomatic distal vasospasm refractory to medical 
therapy in patients with aneurysmal subarachnoid hemorrhage. Neuro-
surgery 69 : 95-101; discussion 102, 2011
288. Sano H, Satoh A, Murayama Y, Kato Y, Origasa H, Inamasu J, et al. : Modi-
fied World Federation of Neurosurgical Societies subarachnoid hemor-
rhage grading system. World Neurosurg 83 : 801-807, 2015
289. Sarker SJ, Heuschmann PU, Burger I, Wolfe CD, Rudd AG, Smeeton NC, 
et al. : Predictors of survival after haemorrhagic stroke in a multi-ethnic 
population: the South London Stroke Register (SLSR). J Neurol Neuro-
surg Psychiatry 79 : 260-265, 2008
290. Sayama T, Inamura T, Matsushima T, Inoha S, Inoue T, Fukui M : High inci-
dence of hyponatremia in patients with ruptured anterior communicating 
artery aneurysms. Neurol Res 22 : 151-155, 2000
291. Schaafsma JD, Sprengers ME, van Rooij WJ, Sluzewski M, Majoie CB, 
Wermer MJ, et al. : Long-term recurrent subarachnoid hemorrhage after 
adequate coiling versus clipping of ruptured intracranial aneurysms. 
Stroke 40 : 1758-1763, 2009
292. Schebesch KM, Proescholdt M, Ullrich OW, Camboni D, Moritz S, Wi-
esenack C, et al. : Circulatory arrest and deep hypothermia for the treat-
ment of complex intracranial aneurysms--results from a single European 
center. Acta Neurochir (Wien) 152 : 783-792, 2010
293. Schievink WI, Schaid DJ, Michels VV, Piepgras DG : Familial aneurysmal 
subarachnoid hemorrhage: a community-based study. J Neurosurg 83 : 
426-429, 1995
294. Schmidt JM, Crimmins M, Lantigua H, Fernandez A, Zammit C, Falo C, 
et al. : Prolonged elevated heart rate is a risk factor for adverse cardiac 
events and poor outcome after subarachnoid hemorrhage. Neurocrit 
Care 20 : 390-398, 2014
295. Schuss P, Güresir E, Berkefeld J, Seifert V, Vatter H : Influence of surgical 
or endovascular treatment on visual symptoms caused by intracranial 
aneurysms: single-center series and systematic review. J Neurosurg 115 : 
694-699, 2011
296. Seiler RW, Reulen HJ, Huber P, Grolimund P, Ebeling U, Steiger HJ : Out-
come of aneurysmal subarachnoid hemorrhage in a hospital population: 
a prospective study including early operation, intravenous nimodipine, 
and transcranial doppler ultrasound. Neurosurgery 23 : 598-604, 1988
297. Seo DH, Kang HS, Kim DW, Park SQ, Song Y, Sheen SH, et al. : Guidelines 
for the management of unruptured intracranial aneurysm. Korean J 
Cerebrovasc Surg 13 : 279-290, 2011
298. Shankar JJ, dos Santos MP, Deus-Silva L, Lum C : Angiographic evalua-
tion of the effect of intra-arterial milrinone therapy in patients with va-
sospasm from aneurysmal subarachnoid hemorrhage. Neuroradiology 
53 : 123-128, 2011
299. Shen J, Pan JW, Fan ZX, Xiong XX, Zhan RY : Dissociation of vasospasm-
related morbidity and outcomes in patients with aneurysmal subarach-
noid hemorrhage treated with clazosentan: a meta-analysis of random-
ized controlled trials. J Neurosurg 119 : 180-189, 2013
300. Shen X, Xu T, Ding X, Wang W, Liu Z, Qin H : Multiple intracranial aneu-
rysms: endovascular treatment and complications. Interv Neuroradiol 
20 : 442-447, 2014
301. Shimamura N, Matsuda N, Satou J, Nakano T, Ohkuma H : Early ambula-
tion produces favorable outcome and nondemential state in aneurysmal 
subarachnoid hemorrhage patients older than 70 years of age. World 
Neurosurg 81 : 330-334, 2014
302. Shimoda M, Hoshikawa K, Shiramizu H, Oda S, Matsumae M : Problems 
with diagnosis by fluid-attenuated inversion recovery magnetic reso-
nance imaging in patients with acute aneurysmal subarachnoid hemor-
rhage. Neurol Med Chir (Tokyo) 50 : 530-537, 2010
303. Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, et al. : No 
effect of enoxaparin on outcome of aneurysmal subarachnoid hemor-
rhage: a randomized, double-blind, placebo-controlled clinical trial. J 
Neurosurg 99 : 953-959, 2003
304. Smith MJ, Le Roux PD, Elliott JP, Winn HR : Blood transfusion and in-
creased risk for vasospasm and poor outcome after subarachnoid hem-
orrhage. J Neurosurg 101 : 1-7, 2004
305. Smith WS, Dowd CF, Johnston SC, Ko NU, DeArmond SJ, Dillon WP, et 
al. : Neurotoxicity of intra-arterial papaverine preserved with chlorobu-
tanol used for the treatment of cerebral vasospasm after aneurysmal 
subarachnoid hemorrhage. Stroke 35 : 2518-2522, 2004
306. Solenski NJ, Haley EC Jr, Kassell NF, Kongable G, Germanson T, Truskowski 
L, et al. : Medical complications of aneurysmal subarachnoid hemor-
rhage: a report of the multicenter, cooperative aneurysm study. Partici-
pants of the multicenter cooperative aneurysm study. Crit Care Med 23 : 
1007-1017, 1995
307. Solomon RA, Smith CR, Raps EC, Young WL, Stone JG, Fink ME : Deep 
hypothermic circulatory arrest for the management of complex anterior 
and posterior circulation aneurysms. Neurosurgery 29 : 732-737; dis-
cussion 737-738, 1991
308. Spetzler RF, Hadley MN, Rigamonti D, Carter LP, Raudzens PA, Shedd 
SA, et al. : Aneurysms of the basilar artery treated with circulatory arrest, 
hypothermia, and barbiturate cerebral protection. J Neurosurg 68 : 868-
879, 1988
309. Spetzler RF, McDougall CG, Albuquerque FC, Zabramski JM, Hills NK, 
Partovi S, et al. : The Barrow Ruptured Aneurysm Trial: 3-year results. J 
Neurosurg 119 : 146-157, 2013
310. Starke RM, Kim GH, Fernandez A, Komotar RJ, Hickman ZL, Otten ML, et 
al. : Impact of a protocol for acute antifibrinolytic therapy on aneurysm 
rebleeding after subarachnoid hemorrhage. Stroke 39 : 2617-2621, 2008
311. Stein M, Brokmeier L, Herrmann J, Scharbrodt W, Schreiber V, Bender M, 
et al. : Mean hemoglobin concentration after acute subarachnoid hem-
orrhage and the relation to outcome, mortality, vasospasm, and brain 
infarction. J Clin Neurosci 22 : 530-534, 2015
312. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. : Euro-
pean Stroke Organization guidelines for the management of intracranial 
aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 35 : 93-
Korean CPG for aSAH | Cho WS, et al.
165J Korean Neurosurg Soc 61 (2) : 127-166
112, 2012
313. Sunderland A, Tinson DJ, Bradley EL, Fletcher D, Langton Hewer R, Wade 
DT : Enhanced physical therapy improves recovery of arm function after 
stroke: A randomized controlled trial. J Neurol Neurosurg Psychiatry 
55 : 530-535, 1992
314. Sundquist J, Li X, Sundquist K, Hemminki K : Risks of subarachnoid hem-
orrhage in siblings: a nationwide epidemiological study from Sweden. 
Neuroepidemiology 29 : 178-184, 2007
315. Tagami T, Kuwamoto K, Watanabe A, Unemoto K, Yokobori S, Matsu-
moto G, et al. : Effect of triple-h prophylaxis on global end-diastolic 
volume and clinical outcomes in patients with aneurysmal subarachnoid 
hemorrhage. Neurocrit Care 21 : 462-469, 2014
316. Tagami T, Kuwamoto K, Watanabe A, Unemoto K, Yokobori S, Matsu-
moto G, et al. : Optimal range of global end-diastolic volume for fluid 
management after aneurysmal subarachnoid hemorrhage: a multicenter 
prospective cohort study. Crit Care Med 42 : 1348-1356, 2014
317. Takebayashi S, Kamiyama H, Takizawa K, Kobayashi T, Saitoh N : The 
significance of intraoperative monitoring of muscle motor evoked po-
tentials during unruptured large and giant cerebral aneurysm surgery. 
Neurol Med Chir (Tokyo) 54 : 180-188, 2014
318. Takeuchi H, Handa Y, Kobayashi H, Kawano H, Hayashi M : Impairment 
of cerebral autoregulation during the development of chronic cerebral 
vasospasm after subarachnoid hemorrhage in primates. Neurosurgery 
28 : 41-48, 1991
319. Takeuchi S, Mori K, Arimoto H, Fujii K, Nagatani K, Tomura S, et al. : Ef-
fects of intravenous infusion of hydrogen-rich fluid combined with intra-
cisternal infusion of magnesium sulfate in severe aneurysmal subarach-
noid hemorrhage: study protocol for a randomized controlled trial. BMC 
Neurol 14 : 176, 2014
320. Taylor CJ, Robertson F, Brealey D, O’shea F, Stephen T, Brew S, et al. : 
Outcome in poor grade subarachnoid hemorrhage patients treated with 
acute endovascular coiling of aneurysms and aggressive intensive care. 
Neurocrit Care 14 : 341-347, 2011
321. Terry A, Zipfel G, Milner E, Cross DT 3rd, Moran CJ, Diringer MN, et al. : 
Safety and technical efficacy of over-the-wire balloons for the treatment 
of subarachnoid hemorrhage-induced cerebral vasospasm. Neurosurg 
Focus 21 : E14, 2006
322. Tewari M, Aggarwal A, Mathuriya S, Gupta V : The outcome after aneu-
rysmal sub arachnoid hemorrhage: a study of various factors. Ann Neu-
rosci 22 : 78-80, 2015
323. Thiele RH, Pouratian N, Zuo Z, Scalzo DC, Dobbs HA, Dumont AS, et al. : 
Strict glucose control does not affect mortality after aneurysmal subarach-
noid hemorrhage. Anesthesiology 110 : 603-610, 2009
324. Todd MM, Hindman BJ, Clarke WR, Torner JC; Intraoperative Hypother-
mia for Aneurysm Surgery Trial (IHAST) Investigators : Mild intraopera-
tive hypothermia during surgery for intracranial aneurysm. N Engl J Med 
352 : 135-145, 2005
325. Togashi K, Joffe AM, Sekhar L, Kim L, Lam A, Yanez D, et al. : Random-
ized pilot trial of intensive management of blood pressure or volume 
expansion in subarachnoid hemorrhage (IMPROVES). Neurosurgery 
76 : 125-134; discussion 134-135; quiz 135, 2015
326. Tseng MY, Al-Rawi PG, Czosnyka M, Hutchinson PJ, Richards H, Pickard 
JD, et al. : Enhancement of cerebral blood flow using systemic hypertonic 
saline therapy improves outcome in patients with poor-grade spontane-
ous subarachnoid hemorrhage. J Neurosurg 107 : 274-282, 2007
327. Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ : Effect of 
hypertonic saline on cerebral blood flow in poor-grade patients with 
subarachnoid hemorrhage. Stroke 34 : 1389-1396, 2003
328. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber 
WN, et al. : Acute systemic erythropoietin therapy to reduce delayed 
ischemic deficits following aneurysmal subarachnoid hemorrhage: a 
phase II randomized, double-blind, placebo-controlled trial. Clinical ar-
ticle. J Neurosurg 111 : 171-180, 2009
329. Tsutsumi K, Ueki K, Morita A, Usui M, Kirino T : Risk of aneurysm recur-
rence in patients with clipped cerebral aneurysms: results of long-term 
follow-up angiography. Stroke 32 : 1191-1194, 2001
330. Vale FL, Bradley EL, Fisher WS 3rd : The relationship of subarachnoid 
hemorrhage and the need for postoperative shunting. J Neurosurg 86 : 
462-466, 1997
331. van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, et 
al. : Impact of cardiac complications on outcome after aneurysmal sub-
arachnoid hemorrhage: a meta-analysis. Neurology 72 : 635-642, 2009
332. van der Schaaf I, Wermer MJ, van der Graaf Y, Hoff RG, Rinkel GJ, Velthuis 
BK : CT after subarachnoid hemorrhage: relation of cerebral perfusion to 
delayed cerebral ischemia. Neurology 66 : 1533-1538, 2006
333. van Heuven AW, Dorhout Mees SM, Algra A, Rinkel GJ : Validation of a 
prognostic subarachnoid hemorrhage grading scale derived directly from 
the glasgow coma scale. Stroke 39 : 1347-1348, 2008
334. van Loon J, Waerzeggers Y, Wilms G, Van Calenbergh F, Goffin J, Plets 
C : Early endovascular treatment of ruptured cerebral aneurysms in pa-
tients in very poor neurological condition. Neurosurgery 50 : 457-464; 
discussion 464-465, 2002
335. Varelas P, Helms A, Sinson G, Spanaki M, Hacein-Bey L : Clipping or coil-
ing of ruptured cerebral aneurysms and shunt-dependent hydrocephalus. 
Neurocrit Care 4 : 223-228, 2006
336. Varma MK, Price K, Jayakrishnan V, Manickam B, Kessell G : Anaesthetic 
considerations for interventional neuroradiology. Br J Anaesth 99 : 75-
85, 2007
337. Veerbeek JM, Koolstra M, Ket JC, van Wegen EE, Kwakkel G : Effects of 
augmented exercise therapy on outcome of gait and gait-related activi-
ties in the first 6 months after stroke: a meta-analysis. Stroke 42 : 3311-
3315, 2011
338. Vergouwen MD, Algra A, Rinkel GJ : Endothelin receptor antagonists for 
aneurysmal subarachnoid hemorrhage: a systematic review and meta-
analysis update. Stroke 43 : 2671-2676, 2012
339. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB : Effect of statin 
treatment on vasospasm, delayed cerebral ischemia, and functional out-
come in patients with aneurysmal subarachnoid hemorrhage: a system-
atic review and meta-analysis update. Stroke 41 : e47-e52, 2010
340. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muiz-
elaar JP, et al. : Definition of delayed cerebral ischemia after aneurysmal 
subarachnoid hemorrhage as an outcome event in clinical trials and obser-
J Korean Neurosurg Soc 61 | March 2018
166 https://doi.org/10.3340/jkns.2017.0404.005
vational studies: proposal of a multidisciplinary research group. Stroke 
41 : 2391-2395, 2010
341. Vermeij FH, Hasan D, Vermeulen M, Tanghe HL, van Gijn J : Predictive 
factors for deterioration from hydrocephalus after subarachnoid hemor-
rhage. Neurology 44 : 1851-1855, 1994
342. Wang PS, Longstreth WT Jr, Koepsell TD : Subarachnoid hemorrhage and 
family history. A population-based case-control study. Arch Neurol 52 : 
202-204, 1995
343. Wang X, Li YM, Li WQ, Huang CG, Lu YC, Hou LJ : Effect of clazosentan 
in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis 
of randomized controlled trials. PLoS One 7 : e47778, 2012
344. Wartenberg KE, Parra A : CT and CT-perfusion findings of reversible leu-
koencephalopathy during triple-H therapy for symptomatic subarachnoid 
hemorrhage-related vasospasm. J Neuroimaging 16 : 170-175, 2006
345. Wartenberg KE, Schmidt JM, Claassen J, Temes RE, Frontera JA, Ostap-
kovich N, et al. : Impact of medical complications on outcome after sub-
arachnoid hemorrhage. Crit Care Med 34 : 617-623; quiz 624, 2006
346. Wermer MJ, Koffijberg H, van der Schaaf IC; ASTRA Study Group : Ef-
fectiveness and costs of screening for aneurysms every 5 years after 
subarachnoid hemorrhage. Neurology 70 : 2053-2062, 2008
347. Wermer MJ, van der Schaaf IC, Velthuis BK, Algra A, Buskens E, Rinkel GJ, 
et al. : Follow-up screening after subarachnoid haemorrhage: frequency 
and determinants of new aneurysms and enlargement of existing aneu-
rysms. Brain 128(Pt 10) : 2421-2429, 2005
348. Westermaier T, Pham M, Stetter C, Willner N, Solymosi L, Ernestus RI, et 
al. : Value of transcranial doppler, perfusion-CT and neurological evalu-
ation to forecast secondary ischemia after aneurysmal SAH. Neurocrit 
Care 20 : 406-412, 2014
349. Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr, Piep-
gras DG, et al. : Unruptured intracranial aneurysms: natural history, clini-
cal outcome, and risks of surgical and endovascular treatment. Lancet 
362 : 103-110, 2003
350. Willinsky RA, Peltz J, da Costa L, Agid R, Farb RI, terBrugge KG : Clinical 
and angiographic follow-up of ruptured intracranial aneurysms treated 
with endovascular embolization. AJNR Am J Neuroradiol 30 : 1035-
1040, 2009
351. Winn HR, Richardson AE, Jane JA : The long-term prognosis in untreated 
cerebral aneurysms: I. The incidence of late hemorrhage in cerebral an-
eurysm: a 10-year evaluation of 364 patients. Ann Neurol 1 : 358-370, 
1977
352. Wong GK, Chan DY, Siu DY, Zee BC, Poon WS, Chan MT, et al. : High-
dose simvastatin for aneurysmal subarachnoid hemorrhage: multicenter 
randomized controlled double-blinded clinical trial. Stroke 46 : 382-388, 
2015
353. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. : Intravenous 
magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): 
a randomized, double-blinded, placebo-controlled, multicenter phase III 
trial. Stroke 41 : 921-926, 2010
354. Yundt KD, Grubb RL Jr, Diringer MN, Powers WJ : Autoregulatory vaso-
dilation of parenchymal vessels is impaired during cerebral vasospasm. J 
Cereb Blood Flow Metab 18 : 419-424, 1998
355. Zhao XD, Zhou YT, Zhang X, Zhuang Z, Shi JX : A meta analysis of treat-
ing subarachnoid hemorrhage with magnesium sulfate. J Clin Neurosci 
16 : 1394-1397, 2009
356. Zwienenberg-Lee M, Hartman J, Rudisill N, Madden LK, Smith K, Eskridge 
J, et al. : Effect of prophylactic transluminal balloon angioplasty on cere-
bral vasospasm and outcome in patients with fisher grade III subarach-
noid hemorrhage: results of a phase II multicenter, randomized, clinical 
trial. Stroke 39 : 1759-1765, 2008
357. Post-stroke rehabilitation: assessment, referral and patient management. 
Post-stroke rehabilitation guideline panel. Agency for Health Care Policy 
and Research. Am Fam Physician 52 : 461-470, 1995
358. Report of World Federation of Neurological Surgeons Committee on a 
universal subarachnoid hemorrhage grading scale. J Neurosurg 68 : 
985-986, 1988
